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ABSTRACT 
This thesis describes an investigation into the roles and effects of nitrogen-donor 
chelating ligands and complexes containing metal centres as tools for molecular imaging. 
Chapter 1 gives a brief introduction to Positron Emission Tomography (PET) imaging, 
the radionuclides and metal centres currently available for therapeutic use, and a 
discussion and comparison between metal and organic-based contrast agents. Chapter 
1 also contains an introduction to macrocycles and their role as ligands, with particular 
focus on azamacrocycles and their applications. Finally, a brief introduction to 
luminescence spectroscopy and optical imaging is made. 
Chapter 2 reports the synthetic procedures used, and gives characterisation data for the 
compounds synthesised and discussed in subsequent chapters. 
Chapter 3 investigates the role of the triazine core of the azamacrocycles, showing some 
compounds of biological interest and the synthesis of new ligands and complexes based 
on a tetraazamacrocycle (DO3A) moiety with a triazine core. One example has been 
successfully used to study the coordination chemistry and structure of different metal 
centres, while another has shown promise with a potential application in mimicking 
dipyridamole compounds. Moreover it has been conducted a study to determinate the 
empirical formula and the nature of the complexes in solution.
Chapter 4 contains an introduction to the benzothiazole group, which has relevance in 
the study of Alzheimer's disease as it is a biological marker for metal-dependant 
formation of Aβ plaques. The synthesis of new ligands derived from several macrocycles 
(including those reported earlier, and those containing an acyclic moiety with a 
benzothiazole core) are reported, including procedures to produce complexes of 
lanthanides and PET-active metal centres including copper, vanadium and gallium. 
Benzothiazole ligands and complexes have been characterised by fluorimetry, allowing 
discussion of the role of the ligand.  
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Finally, in chapter 5 results for one compound (V-DO3A-Bz-epox) are reported, showing 
encouraging results in vivo studies (in a mice model) as a novel PET contrasting 
compound. 
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CHAPTER 1 
INTRODUCTION 
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1.1 - POSITRON EMISSION TOMOGRAPHY
During the past ten years molecular imaging has become the technique of choice for the 
management of patients with cancer and other diseases, as well as a valuable 
investigative method for the study of drug action and the development of new therapeutic 
approaches. Positron Emission Tomography (PET) is a nuclear medicine tomography 
modality and at present one of the fastest growing research areas. PET imaging is 
currently used in three main areas: cancer diagnosis and treatment, cardiac surgery and 
neurology. In cardiac surgery the PET imaging finds application mainly through the use 
of 13N-ammonia to measure myocardial perfusion, and how the heart functions through 
blood flow studies. In neurology PET is used for management of brain tumours, 
especially those causing para neoplastic symptoms, and has been shown to give earlier 
diagnosis and determination of dementia like Alzheimer's disease. Finally oncological 
PET is used for a wide variety of reasons as well as diagnosis of active and regressive 
tumours, the aggressiveness of tumour, the identification and spread of the cancer, and 
the response to therapies. 
The wide possible applications of PET imaging led researchers and engineers to improve 
different technical aspects. The imaging regime requires a tracer that can be 
administered to the patients; typically the structure can be divided in two different 
moieties, a biomolecule that must interact with the selected targeting group and a 
positron emissive radionuclide (Figure 1.1). After administration, suitable time is allowed 
for the radiomolecule to locate the tumour mass or the β-amyloid protein in the case of 
Alzheimer's disease for example, then the patient is placed within a detector and an 
image of the scan recorded and analysed. This is a fast growing research field, many 
results have been obtained since the first human scan in 1974; with more specific 
molecules able to react better with the targeting group and leaving the patients less 
exposed to the radionuclide, with more and more sensitive detectors being designed, 
allowing patients to be scanned with a higher resolution and at a higher turnover. 
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Currently modern PET scanners are combining different imaging modalities to allow 
fusion of various imaging techniques, such as PET-CT (Computed Tomography) or PET-
MRI (Magnetic Resonance Tomography), giving anatomic and metabolic information; so 
that areas of abnormality on the PET imaging can be more perfectly correlated with 
anatomy with the second technique.[1] 
Figure 1.1: structure of a chelate radionuclide with linker[2] 
1.1.1 - Physical foundation of PET 
The essential concept underpinning positron emission tomography is the capacity of a 
positron to annihilate an electron with the resultant emission of two photons in opposite 
directions. The positron is a subatomic particle with the same mass of an electron but 
opposite charge, which was postulated for the first time by Dirac in 1928 and observed 
experimentally by Anderson in 1932.[3] When a positron interacts with an electron, it 
generates two photons that are emitted simultaneously in opposite directions. Positron 
emission is the result of radioactive decay, where an unstable nucleus loses energy 
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energy by emitting a β+ particle and an anti-neutrino, which is required to conserve the 
lepton number of the nuclear reaction.  
The radioactive process that results in positron emission is known as nuclear 
transmutation, which is the conversion of one element into another through radioactive 
decay,  in this case the production of a positron and anti-neutrino (*) as product of the 
decay of a proton into a neutron, following the general equation: 
where Y is the stable neutral daughter nucleus with an atomic number one less than the 
generator element, and to keep the neutrality an electron is also emitted; X is the proton 
rich atom that undergoes radiative decay when a proton converts to a neutron with the 
emission of a positron. The ejected positron can have an energy up to a given maximum 
which is typically much higher than thermal energy and is slowed by collision with 
neighbouring atoms until its energy matches that of electrons in the surrounding atoms, 
the collision can create a positronium, a new particle combining a positron and electron 
with an half life of around 10-7 s. The probability of positronium faormation is higher in 
gases and metals and much lower in human tissue where direct annihilation is more 
favourable. 
Figure 1.2: emission and annihilation of a positron 
Consequently, after the positron is emitted, it travels a short distance before it is 
annihilated by combination with an electron in a near neighbouring atom (Figure 1.2). 
PN v

511keV
511keV
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The annihilation process generates two photons of the same energy 511 keV, which can 
be calculated using Einstein's energy-mass equation: 
The two photons are emitted in almost exactly opposite directions and are detected by 
the PET detector (scintillation counters). Importantly, the energies of the photons are 
much different from the energies of photons arising from natural background or other 
non-PET isotopes limiting improvinf signal-to-noise ratios.[3-4]
1.1.2 - Radionuclides in PET 
The first radionuclides used in PET were isotopes such as 18F, 15O, 13N and 11C that were 
incorporated into small molecules with biology activity.[5] One of the best molecules for 
investigating biological processes, specifically glucose metabolism, is 18F-
Fluorodeoxyglucose (18F-FDG), which is used to image lung, heart, brain and tumours in 
oncology (Figure 1.3). 
Figure 1.3: 18F-FDG
Unfortunately, drawbacks such as short half-life (15O = 2.03min, 11C = 20min, 18F = 109.8 
min) and rapid clearance do not often permit a full investigation of all biological 
processes. These problems have driven the research towards another kind of 
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radionuclides, the metals. Radiometals like Zr, Y, In, Ga and Cu are able to emit positrons 
and, most importantly, possess a longer half-life (see table 1).[6] 
Isotope t1/2 (h) Decay Mode E β+ (keV) Production Method
60Cu 0.4 β+ (93%) 3920, 3000 cyclotron, 61Ni(p,n) 60Cu
EC (7%) 2000
61Cu 3.3 β+ (62%) 1220, 1150 cyclotron, 61Ni(p,n) 61Cu
EC (38%) 940, 560
62Cu 0.16 β+ (98%) 2910 62Zn/ 60Cu generator
EC (2%)
64Cu 12.7 β+ (19%) 656 cyclotron, 61Ni(p,n) 64Cu
EC (41%)
β- (40%)
66Ga 9.5 β+ (60%) 4150, 935 cyclotron, 63Cu(α,nγ)66Ga
EC (10%)
68Ga 1.1 β+ (90%) 1880 68Ge/68Ga generator
EC (10%)
86Y 14.7 β+ (33%) 1221 cyclotron, 86Sr(p,n) 86Y
EC (66%)
89Zr 78.5 β+ (23%) 897 cyclotron, 86Y(p,n) 89Zr
EC (77%)
Table 1: properties of selected PET imaging isotopes, EC = Electron Capture, some low abundance 
positrons have been omitted for clarity[2, 7] 
The half-life of the radiometals is an important factor to consider. For practical 
applications, the half-life must be long enough to allow for the synthesis of the probe 
molecule and for its diffusion into the body, but it should also be as short as possible in 
order to limit the patient exposure to the radiation. Consequently, since different clinical 
applications might have different timescales for the distribution and localisation of the 
probe molecule at the site of interest (e.g. antibodies tend to have a much longer 
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biological half-life than small molecules), it is an advantage to have the ability to design 
probes of varying half lives. This in turn requires the use of different isotopes of different 
elements and thus the chemical approaches to the synthesis of these probes may vary 
widely and will require skills in inorganic, organic and biologically related chemistry. 
In order to access a range of half lives, it is necessary to utilise metal isotopes. Since it 
is difficult to incorporate radiometals in the structure of small biological molecules, a 
common way to overcome this problem is to chelate the metal using a polydentate ligand 
and a linker which is able to interact with a biological molecule.[2] Of the various potential 
applications of PET, the incorporation of PET isotopes into antibodies is of current 
interest and has currently only been done with generic metal-binding ligand systems that 
are not optimised for metal binding (thus have limitations arising from loss of the 
radiometal during biological distribution in vivo and consequent loss of imaging 
specificity).[8] 
Radiolabeled monoclonal antibodies (mAbs) have shown a considerable potential for 
diagnosis and treatment of cancer. Molecules like 64Cu-DOTA-T/N-trastuzumab or 89Zr-
DFO-T/N-transuzumab[9] are able to specifically bind to target cells and attack or reveal 
the presence of a cancer. One of the biggest problems is the stability of the imaginging 
agent in the body. If the complex is not sufficiently stable, the metal can be released by 
the chelator and accumulate in the body and/or in non target organs. For example, 89Zr 
is a bone seeking radiometal and if released can build up in the bones at the joints. 
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1.2 - MACROCYCLES
The significant advantage of radioactive metals is the longer half-life compared to the 
organic molecules. Unfortunately, they cannot be normally be directly incorporated into 
small molecules with relevant biological activity. Bifunctional chelators (BFC) are an 
attractive method to circumvent this problem, by providing a core to facilitate site-specific 
delivery to a biological target and another core to bind the "hot" metal. Normally a 
macrocycle is defined as cyclic polydentate ligand with 8 or more ring members and at 
least three donor atoms.[10] Macrocyclic chemistry is a vast field and there are different 
kind of compounds that can be included in this class like porphyrin rings, catenanes, 
crown ethers, cyclophanes, or cryptands to name a few (Figure 1.4).
Figure 1.4: examples of macrocycles
Having a huge number of compounds included in this category make also possible varied 
uses such as liquid crystals[11] or surfactants[12]; but even for biological applications as 
anti-HIV / AIDS[13] treatments, biological tracers[14], protein labelling[15], antitumour 
agents[16] and imaging agents.[17] The main characteristics of these compounds are the 
cavity size, the dimension of the ring, the number and type of possible donor positions, 
steric effects present on the ring, and substitute groups able to change the number of 
donor atoms ligand are features that can change or influence the coordination of the 
metal.[18]
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1.2.1 - Azamacrocycles
Azamacrocycles are a particular group in the macrocyclic ligand field, with all the 
compounds presenting nitrogens as donor atoms. The ability to bind a suitable metal for 
imaging is also improved by the easy capacity to functionalise the amine moieties on the 
ring. There is wide range of azamacrocycles in literature[19], but actually the research is 
more focused on the 1,4,7-triazacyclononane (TACN), 1,4,7,10-tetraazacyclododecane 
(cyclen) and 1,4,8,11-tetraazatetradecane (cyclam) (Figure 1.5).
Figure 1.5: TACN (left), cyclen (centre) and cyclam (right) structures
The macrocycles have found applications in many biological areas, like radioactive 
diagnosis, cancer treatment or magnetic resonance imaging (MRI) contrast agent.[19] As 
MRI agents the main results have been obtained using a gadolinium(III) metal bound to 
a functionalised ring with carboxylate arms called 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA)[20] or 1,4,8,11-tetraazatetradecane-1,4,8,11-tetraacetic 
acid (TETA)[21] depending on which ring is used (Figure 1.6). 
Figure 1.6: DOTA (left) and TETA (right) structures
10 
1.2.2 - Chelate effect
The chelate effect can be described as the higher stability constant of a chelated complex 
than a non-chelated analogue. It can be demonstrated by comparing the reaction of a 
chelating ligand and a metal ion with the corresponding reaction involving unidentate 
ligands, an example being: 
through the equation
It is possible to see that the Gibbs free energy is related to the equilibrium constant K, a 
larger equilibrium constant means a more stable complex; furthermore ΔG° depends on 
both enthalpy and entropy. While the enthalpy values are comparable due to the bond 
formation similar for both of the complexes, it is simple to see how the main difference is 
considering the entropy. The first equation involves three species being converted in 
three new species, not resulting in a particularly large entropy change. However the 
second equation is different, there are initially two different species that are converted 
into three new species, representing an increase in disorder in the system. This means 
that the entropy term of the third equation (- TΔS°) makes a larger negative contribution 
to ΔG°, resulting in a larger equilibrium constant.[22]
An additional factor to consider is the tethering effect, if the chelate and the monodentate 
ligand are in competition to coordinate the metal both have the same chance to bind the 
metal the first time. After that the chelate ligand is more likely to coordinate the metal 
11 
centre with a second pendant, because the second donor is closer than an unlinked 
donor not coordinated.[18] This is essentially a kinetic effect.
As examples of chelate ligands that have found large application in the imaging 
chemistry there are 3,4,3-LI-1,2-HOPO (HOPO)[23] and deferoxamine (DFO) 
(Figure 1.7). In particular DFO has been one of the most commonly employed chelating 
agents since 1970s, originally isolated from the fungus Streptomyces pilosus. The main 
use in nature and in medicine is in chelation therapy to treat iron overload. DFO is a 
hexadentate ligand, provided by the three bidentate hydroxamate moieties it can provide 
a good Fe complexation even in vivo, coordinating the metal centre in a distorted 
octahedral geometry.[24] Moreover considering these features made DFO a possible 
available ligand to be used with 68Ga. Fe(III) and Ga(III) have similar Van der Waals radii, 
62 pm for Ga+3 and 65 for Fe+3, and according to the high charge density of the positive 
ion (+3) and small size, both prefer hard donors as ligands. Both Fe(III) and Ga(III) are 
6 coordinate favouring octahedral geometry.[25] Considering these features it has been 
possible develop and test new ligands, bearing 68Ga and 89Zr as imaging metal, and 
linking the complex to an antibody to localise the desired compound.[5, 8-9, 23a, b, 26]
Figure 1.7: DFO (top) and HOPO (bottom) structures
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1.2.3 - Macrocyclic effect
The macrocyclic effect may be regarded as an extension of the chelate effect. 
Macrocyclic ligand complexes tend to high stabilities and can display considerable kinetic 
inertness. Enthalpic and the entropic parameters are the two factors that must be 
evaluated considering the stability of a compound. The entropy is the cause of the 
increased stability for the chelate compound compared to unidentate analogues. The 
increase of disorder cannot be a factor analysing the equilibrium constants between a 
multidentate ligand and a macrocycle, since both reactions tend to have positive 
(favourable) entropy terms. Furthermore considering the macrocycle ligand there is a 
lower rotation freedom than a linear multidentate ligand, implying slower complex 
formation kinetics in comparison to chelate ligands. Thus the macrocyclic effect is largely 
enthalpic in origin. For example, if the macrocyclic ligand has the right cavity size for the 
metal that is going to coordinate, the metal-donor bonds will be significantly stronger that 
those that are strained.[22]
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1.3 - LUMINESCENCE
When molecules are exposed to electromagnetic radiation there is an interaction 
between the electric field of the incident radiation and the electrons of the molecule. If 
the energy of the photon is the same as the energy difference between two electronic 
states of the molecule, there is a high probability that the compound will absorb a photon 
and pass from the ground state to an excited state of higher energy. This is the 
absorption process. The molecule, in returning to the ground state, loses energy that can 
be emitted as a photon. This process is known as luminescence. Radiation emitted or 
transmitted by a sample can be used to extract information on the electronic structure of 
the compound itself. The most common techniques to observe this phenomenon are the 
ones that use the wavelengths of electromagnetic radiation between 100 and 1000 nm. 
This spectrum includes the near UV, the visible that covers between 400 and 700 nm, 
and the near infrared. The photon energy range is around from 1 to 10 eV (28-280 kcal 
mol-1). 
1.3.1 - Fluorescence and Phosphorescence 
When electrons move from a higher and excited level of energy to one lower, the energy 
released can be emitted as electromagnetic radiation. This phenomenon is called 
luminescence. The features about wavelengths and intensity of the emitted radiation are 
controlled by some rules at the base of the molecular excitation, in fact not all the 
transition between the energy states are allowed. The selection rules are complex and 
deduced from quantum mechanics. A full discussion of these rules is beyond the scope 
of this thesis, but the general law states that transitions are allowed when the difference 
between the spin quantum numbers of the two states is zero (ΔS = 0, spin conservation). 
Generally the rule envisions the spin multiplicity, 2S+1, that represents the number of 
possible orientations of spin angular momentum along the z direction. In this case the 
spin configurations can be classified as singlet (2S+1 = 1, S = 0), doublet (2S+1 = 2, S 
= 1/2), triplet (2S+1 = 3, S = 1), and so on. 
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Most organic molecules after the absorption of a quantum of light undergo a transition 
from the singlet ground state to an excited singlet state in a time scale of  10-15 s with 
the resulting excited singlet state characterised by a spin quantum number with S = 0. 
An electron promoted to an excited state can have the spin aligned or not aligned to the 
one left in the ground state (Figure 1.8). So, every promotion can, theoretically, create 
two different states, a singlet and a triplet; the triplet that has a lower energy level but it 
is not accessible due to the selection rules. 
S0
S1
T1
A B
C
D
E
E
E
F
Figure 1.8: simplified Jablonski's diagram that describes the transition from the ground state (S0) to one 
excited (S1, singlet, T1, triplet) and from this one to the ground state. The arrows represent 
radiative transaction, those dotted non radiative vibrational relaxation. A: absorption; 
B: fluorescence; C: intersystem crossing; D: internal conversion; E: vibrational relaxation; 
F: phosphorescence
Every excitation/relaxation process can be explained in the scheme above. When the 
photon is absorbed the allowed transition is between the ground singlet state, S0, and 
the excited singlet state, S1 (ΔS = 0). The Franck-Condon principle rules that these 
transitions can be represented by the vertical lines in the figure 1.9, due to the fact that, 
during the electronic transition, the nuclear framework does not react, as the vibrational 
transitions occur much slower. 
Immediately after the excitation, and before any kind of photochemical reaction or 
emission of radiation starts, there is a sequence of events. First of all there is an "internal 
En
er
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conversion": it does not matter which vibrational level of the excited singlet state has 
been reached, there is always a quick return to the lowest vibrational level accessible of 
the excited singlet state, without any emission of radiation, the excess of energy is 
released as heat (non radiative recombination), in a time scale on the order of 10-12 s and 
all the molecules reach the ground vibrational level of the electronic excited state 
(Kasha's rule). The average time scale in an excited electronic state is relatively longer: 
10-9 s and all the molecules can relax vibrationally before the decay of the excited state. 
Therefore it is from this state that the molecules decay to the ground electronic state; 
this relaxation results in the emission being of lower energy than the excitation, and the 
difference between the two energies levels is referred to as the Stokes shift. 
The behaviour of the molecules until this point is indistinct; the first different depends 
from the surrounding molecules; if these are able to absorb the remaining energy in 
excess of the excited molecule, this can complete its relaxation via non radiative 
recombination, otherwise fluorescence and phosphorescence processes can be 
detected. In order to have a fluorescence process, the molecule must reach, via non-
radiative way, the lowest vibrational level of the excited electronic state, then the excess 
of energy is emitted as radiation in a time scale of 10-9 - 10-8 s. The transition is towards 
the lower energetic level and the fluorescence spectrum is referred to the vibrational 
structure characteristic of the lowest electronic state; this means that the relaxation 
process can lead to any vibrational level of the ground state. For this reason the observed 
emission (and absorption) spectra are broad and affected by changes in temperature. 
The relaxation process can also follow a second mechanism: if the molecule has a 
accessible triplet state in the excited electronic state, with energy slightly lower than the 
singlet excited state. There is also the possibility that the potential energy curves of the 
two states can cross each other as reported in figure 1.10. 
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Figure 1.9: Potential energy levels for a diatomic molecule. 1, excitation; 2, fluorescence; 
3, phosphorescence; 4, internal conversion of vibrational states S1 and T1; 
5, intersystem crossing 
Therefore there is the possibility of conversion from singlet to triplet called intersystem 
crossing; process that involves the spin-orbit interaction. Simplifying, it regards the 
interaction between the spin magnetic moment and the electron magnetic moment, the 
rotation of the electron around the nucleus; and the interaction is particularly relevant 
considering atoms with a high atomic number like S, Br, I, and so on. 
The magnetic interaction can happen also with the spin magnetic dipole of unpaired 
electrons of the compounds, for example in presence of transition metals with unpaired 
electrons in the d orbitals (paramagnetic complexes). Once the interaction has taken 
place, the molecule gives energy to the environment in a non-radiative way until to reach 
the vibrational ground of the triplet excited electronic state. This state is lower than the 
singlet excited state and the molecule cannot relax because the transition to the ground 
state is not allowed, being a passage from a triplet state to a singlet (ΔS ≠ 0), but the 
spin/orbit interaction, that was responsible also for the intersystem crossing breaks the 
selection rule and allows a relaxation, even if particularly slow. The light emitted from this 
transition is the classical phosphorescence. Since the transition from triplet to singlet is 
forbidden, the average time scale of the triplet state is quite long, from 10-3 to 103
seconds, therefore the phosphorescence can be observed also after the exciting 
radiation has been turned off. 
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1.3.2 - Lifetimes 
One of most important differences between the fluorescence and phosphorescence is 
the length of the emissive lifetime. The lifetime ( ) is defined as the average time that 
molecules spend in the excited state before relaxing to the ground state. From the 
excited state for a compound there are different paths to relax to the ground state. A 
molecule can be subject to a chemical process given a different product ( ), can release 
in a non-radiative way the energy absorbed (knr) as mentioned and finally can relax in 
the radiative process, with the release of the energy from the excited state as light (kr). 
The lifetime of the excited state can be expressed as the rates of the three relaxation 
processes mentioned before as the equation: 
The equation can be rewritten considering the luminescence properties of a metal 
complex compound and expressed in terms of the rates of luminescence ( ), intersystem 
crossing, ISC ( ) and internal conversion, IC ( ). 
1.3.3 - Quantum yield 
Another important parameter in fluorescence is quantum yield (Φ), which is defined as 
the number of emitted photons in relation to the number of photons absorbed. 
The efficiency of the radiative process can be expressed by the quantum yield, 
considering the radiative emission process and also the rate of non radiative decay knr; 
to have an efficient quantum yield, close to unity, the luminescence must be much 
greater than the non-radiative emission process and the term can be arranged in the 
following equation. 
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1.3.4 - Lanthanides as luminescence probes 
The desirable features for a luminescent probe are fundamentally a large stokes shift 
between the emission and absorption spectra and a long luminescence lifetime. 
Considering the metals, these features can be found in the d-block and f-block 
(lanthanide) series. Lanthanides have a wide scope of emission profiles in the UV, visible 
or NIR regions, as well as a larger Stokes shifts than d-block metals and significantly 
longer luminescence lifetimes. However, f - f transitions associated with this series are 
forbidden due to the Laporte rule, and thus these transitions have low molar 
absorptivities. To resolve this disadvantage, the metal can be coordinated to a chelate 
molecule that possesses a light harvesting ‘antenna group’ (Figure 1.10).
Figure 1.10: representation of an antenna system[27]
The antenna is often an organic compound that can easily absorb energy (as the 
electronic transitions are fully allowed) and transfer it to the 4f excited state of the metal, 
often a triplet excited state. As example of cell imaging is that reported by Wong;[28]; the 
group synthesised europium and terbium complexes coordinated to a DO3A macrocycle 
and tested in vitro on human cervical carcinoma cell (HeLa) to investigate the time-
uptake and localization profile, showing that the compounds can enter in the cancer cells 
effectively and that the uptake depends from the concentration of the solutions used 
(Figure 1.11). 
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Figure 1.11: one of the compound synthesised and tested on human cervical carcinoma cells[28]
Another application for the lanthanide associate to a macrocycle has been developed by 
Hermann,[29] binding an europium metal centre to a DO3A ring. The compound has 
revealed a high sensitivity to the concentration of different anion; for instance, the 
replacement of the two molecules of water coordinated to the europium with picolinate 
acid increases the intensity of the luminescence probes, this due to the fact that the 
picolinate anion works better as antenna for the complex and the substitution of the water 
molecules removed the quenching factor provided by the vibrational O-H bonds. 
The replacement of molecules of water can be obtained by substitution with another 
anion or changing the coordination geometry of the compound. Raymond's group 
investigated the geometry of 1,2-HOPO derivates coordinating an europium metal 
centre[30] (Figure 1.7). The luminescence properties are influenced by the length of the 
central bridge of the ligand, a short bridge constraint the structure in a geometry that 
allowed water in the inner coordination sphere, while increasing the length of the central 
bridge allows to the ligand a better protection of the metal centre, removing the 
luminescence quenching factor provided by the O-H bonds.
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1.3.5 - Optical Imaging
The luminescence properties described have found application in the optical imaging, in 
particular in fluorescence microscopy.[4] The advantages of this technique are multifold, 
with high resolution at cellular level, high sensitivity and low cost; unfortunately there are 
also some problems with this technique as background emission (autofluorescence), 
photobleaching that is photochemical loss of imaging agent, low penetration in the 
tissues and the risk of damage to the tissues using an excitation lambda near the 
ultraviolet, make it unsuitable for in vivo excitation. Thus optical imaging is a perfect 
technique to understand biological pathways especially at a cellular level or to quantify 
and localize the uptake of a molecule in a cell. 
Benzothiazoles are a perfect example of organic compounds with luminescence 
properties that can be used with the confocal microscopy. As previously mentioned 
benzothiazoles are utilised to stain β-amyloids but have found applications as antitumor 
agents.[31] Steven's group synthesised different 2-(4-aminophenyl)benzothiazoles 
derivates and investigated them as novel class of antitumor agents. The compounds 
have been tested in vivo and in vitro on various cell lines, resulting ineffective on prostate, 
colon, ovarian, melanoma and bladder cell lines, but some compounds have been 
discovered with an high cytotoxic activity against mammary carcinoma. The mechanism 
of action has not been fully understood and explained but it has been possible to 
investigate the uptake of two compounds into two cell lines through the confocal 
microscopy at different concentrations and after 24h, 72h and 7 days exposure (Figure 
1.12).  
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Figure 1.12: Confocal microscopy photographs of one compound tested on tumor breast cell lines after 
24h exposure to 30 μM solution.[31]
As previously reported benzothiazoles can be even used to stain β-amyloid and the topic 
will be treated more deeply in the chapter 4. Storr's group synthesised a new class of 
ligands including a benzothiazole core combined with 1,2,3-triazole moiety.[32] The study 
investigates and characterises the photophysical properties of the compounds and tests 
them ex vivo on mouse brain sections with the presence of β-amyloids. The 
benzothiazole derivate shows a high-energy absorption peak at 313 nm and λem = 391 
nm, then the emission and excitation spectra has been recorded in absence and 
presence of β-amyloids plaque, using a 50 μM solution, showing a reduced fluorescence 
emission intensity around the 20%, a behaviour opposite to the classic ThT, which shows 
and increase in the emission intensity. Finally the molecule has been tested with and 
anti-Aβ antibody to see if able to bind the plaques present in the mouse brain sections 
(Figure 1.13) 
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Figure 1.13: Fluorescence microscopy images of β-amyloids aggregate stained with the ligand tested (left), 
the anti-Aβ antibody (centre) and the two images merged (right).[32]
As the image shows the ligand is able to bind and stain Aβ plaques with the emission 
recorded equal to ~ 470 nm, leaving the possibility of further development in this new 
class of ligands. 
As mentioned not only the organic molecules are used with the confocal microscopy, 
Long's group[33] synthesised new compounds based on rhodamine, an organic molecule 
widely used to determine the lower mitochondrial potential in the tumour cells, bearing a 
DO3A macrocycle to coordinate the lanthanide metals. The study investigated the 
luminescence properties of four complexes of Gd and Tb and even the in vitro and in 
vivo studies through the confocal microscopy of human embryonic kidney cells (HEK293) 
and primary mouse islet cells. The rhodamine moiety of the compound, using excitation 
light at 560 nm, yielding an emission band centred at 580 nm, with a small but expected 
Stokes shift. The Tb(III) complexes were investigated under excitation at λex = 310 nm, 
showing a stronger intensity and a longer lived emissive state (λem = 490, 545, 585 and 
620 nm), proving an efficient ligand for terbium(III) energy transfer. Unfortunately, due to 
the optical cut-off of many commercial confocal microscopy set-ups, it is generally 
impossible to use the λex of the Tb complex in vitro or in vivo; so taking advantages of 
the possibility to use of a dual modal technique (MRI/fluorescent) one of the gadolinium 
complexes has been tested, showing the accumulation properties of the compounds in 
the mitochondria of HEK cells. 
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CHAPTER 2 
EXPERIMENTAL 
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2.1 - EXPERIMENTAL AND INSTRUMENTS
Techniques and instruments: All synthetic procedures and manipulations were 
performed under dry nitrogen using standard Schlenk line techniques.  
Solvents were freshly distilled under N2 before use over standard drying agents. 
All non-synthesised chemicals were obtained commercially from Sigma-Aldrich, Alfa 
Aesar, Fluorochem, CheMatech and Apollo and used as received. 
The NMR spectra were recorded on a Bruker DPX-500 instrument at 500 MHz (1H), and 
125 MHz (13C), Bruker DPX-400 instrument at 400 MHz (1H) and 100 MHz (13C). 
Chemical shifts were determined relative to 85% H3PO4 (δP = 0 ppm) or 
tetramethylsilane (δH/C = 0 ppm) and are given in ppm. 
Infrared spectra were recorded either as KBr disks on a Jasco FT/IR-660 Plus 
spectrometer or on a Shimadzu IRAffinity-1S spectrometer equipped with an ATR 
attachment. 
Mass spectra of all the samples have been measured by direct injection into a Waters 
Low Resolution ZQ Mass Spectrometer at Cardiff University.
UV-Vis measurements were performed on a Perkin Elmer Lambda 20 UV/Vis 
spectrometer or a Shimadzu UV-1800 spectrometer.
All photophysical data was obtained on a JobinYvon-Horiba Fluorolog-3 spectrometer 
fitted with a JY TBX picosecond photodetection module and a Hamamatsu R5509-73 
detector. 
Absorbance measurements were performed on a BMG Labtech FLUOstar Omega plate 
reader. Samples were examined within a 4titude 4ti-0234 UV96 well plate. Data analysed 
by Omega Control Software and MARS data analysis software. 
X-Ray Crystallography: Data were collected by Crystallography National Service at 
University of Southampton.  
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PET experiments were performed by Dr. Stephen Paisey, PETIC centre Cardiff, with 
mice provided by Professor Paul Morgan and Dr. Timothy Hughes's research group, 
School of Medicine, Cardiff University.  
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2.2 - SYNTHESIS OF LIGANDS AND COMPLEXES
2.2.1 - Triazine core ligands and complexes 
4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (TzMorphCl2)
The compound was prepared based on a modified literature method.[1] Cyanuric chloride 
(25.0g, 135.6mmol) was dissolved in acetone (150mL) and added to ice water (150mL) 
to form a slurry, and cooled to 0°C. Morpholine (11.81g, 135.6mmol) was dissolved in 
acetone (120mL), and added dropwise to the stirred solution. NaHCO3 (11.39g, 
135.6mmol) was added portion-wise so as to keep the pH neutral. The solution was 
warmed to room temperature and stirred for 18 hours. The white solid was collected by 
filtration and recrystallised from hot EtOH yielding the title product as a colourless solid 
(27.4g, 116.6mmol, 86%). 1H NMR (500 MHz, CDCl3, ppm) δH: 3.85 - 3.82 (m, 4H), 3.72 
– 3.69 (m, 4H); 13C NMR (125 MHz, CDCl3, ppm) δC: 170.4, 164.1, 66.4, 44.5.
4,4’-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (TzMorph2Cl)
The compound was prepared based on a modified literature method.[1] TzMorphCl2
(27.4g, 116.6mmol) was dissolved in acetone (100mL) and added to ice water (150mL) 
to form a slurry. Morpholine (10.15g, 116.6mmol) was dissolved in acetone (100mL) and 
added dropwise to the solution. NaHCO3 (9.79g, 116.6mmol) was added portion-wise so 
as to keep the pH neutral. The solution was stirred for 18 hours at room temperature, the 
solid collected by filtration and recrystallised from hot EtOH, yielding the title product as 
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colourless crystals (23.0g, 80.5mmol, 69 %). 1H NMR (500 MHz, CDCl3, ppm) δH: 3.81 
– 3.69 (m, 4H), 3.68 – 3.64 (m, 4H); 13C NMR (125 MHz, CDCl3, ppm) δC: 169.7, 164.5, 
66.6, 43.9.
1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (DO3A) 
The compound was prepared by literature methodology.[2] To a suspension of cyclen 
(1.00g, 5,8mmol) and sodium acetate (1.57g, 19.2mmol) in dimethylacetamide (20mL) 
at -20°C was added a solution of tert-butyl bromoacetate (3.73g, 19.2mmol) in 
dimethylacetamide (5mL) dropwise over a period of 30 min. The temperature was 
maintained at -20°C during the addition, after which the reaction mixture was allowed to 
come to room temperature. The mixture was left under stirring overnight. The reaction 
mixture was poured into water to give a clear solution. Solid potassium bicarbonate was 
added until the product precipitated as white solid. The precipitate was collected by 
filtration and dissolved in chloroform. The solution was washed with water, dried with 
MgSO4, filtered and concentrated in vacuo (3.17g, 5.3mmol, 92%). 1H NMR (400 MHz, 
CDCl3, ppm) δH: 1.44 (s, 9H), 1.45 (s, 18H), 2.86 (m, 4H), 2.91 – 2.92 (m, 8H), 3.08 (m, 
4H), 3.28 (s, 2H), 3.37 (s, 4H); 13C NMR (125 MHz, CDCl3, ppm) δC: 28.1, 28.2, 47.6, 
48.7, 49.0, 51.1, 51.3, 58.4, 81.4, 82.0, 169.8, 170.5. 
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Tri-tert-butyl 2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-
tetraazacyclododecane- 1,4,7-triyl)triacetate (TzMorph2DO3A)
TzMorph2Cl (1.52g, 5,3mmol), DO3A (3.17g, 5.3mmol) and NaHCO3 (0.895g, 10.6mmol) 
were refluxed in acetonitrile (30mL) under an atmosphere of nitrogen for three days. The 
mixture was cooled down to room temperature and the solvent was removed in vacuo, 
and the solid dissolved in chloroform, washed with water, brine and then dried over 
MgSO4. The solvent was removed in vacuo, yielding a colourless oil (2.19g, 2.87mmol, 
54%). 1H NMR (400 MHz, CDCl3, ppm) δH: 1.43 (s, 9H), 1.45 – 1.46 (m, 18H), 2.81 –
2.73 (m, 12H), 3.07 – 3.04 (t, 4H, J = 6.0Hz), 3.33 – 3.20 (m, 6H), 3.72 – 3.69 (m, 16H). 
2,2’,2”-(10-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1,4,7,10-tetraazacyclododecane- 
1,4,7-triyl)triacetic acid (TzMorph2DO3A)
TzMorph2DO3A (1.64g, 2.15mmol) was dissolved in dichloromethane (10mL) and 
trifluoroacetic acid (9.79g, 85.87mmol) was added. The solution was stirred at room 
temperature for 48 hours, obtaining a yellow solution. The solvent were removed in 
vacuo, and the residue solid was dissolved in methanol (~10mL), this was repeated at 
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least three times, yielding an off pale brown oil. The oil was treated with Et2O, yielding a 
white solid (1.12g, 1.88mmol, 87%). 1H NMR (400 MHz, MeOD, ppm) δH: 2.68 – 3.37 
(br m, 16H), 3.44 – 3.54 (br m, 6H), 3.56 – 3.68 (m, 16H); IR (max, cm−1) 2858 (s), 1728 
(s), 1683 (s), 1550 (s), 1532 (s), 1487 (s), 1441 (s), 1362 (s), 1311 (s), 1288 (s), 1258 
(s), 1204 (s), 1181 (s), 1155 (s), 1132 (s), 1114 (s), 1087 (s), 1070 (s), 1009 (s), 981 (s), 
1019 (s), 912 (s), 880 (s), 861 (s), 830 (s), 808 (w). 
2.2.2 - Metal complexes with TzMorph2DO3A (Et3N method) 
All the complexes have been synthesised following the same procedure. 
TzMorph2DO3A (0.300g, 0.50mmol) were dissolved in MeOH (~3mL). The metal salt 
was dissolved in MeOH (~2mL) and added to the ligand solution. The pH of the solution 
corrected to basic pH adding Et3N until there was the formation of a precipitate. The solid 
was separated by centrifuge. 
Ni(II)-TzMorph2DO3A 
NiCl2*6H2O (0.120g, 0.50mmol) was dissolved in MeOH, obtaining a purple solution. MS 
(HR ES-) calc. for C25H39N9O8Ni (M - H+) 651.2275 found 651.4038. 
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Y(III)-TzMorph2DO3A 
Y(OTf)3 (0.270g, 0.5mmol) was dissolved in MeOH, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H38N9O8YNa (M + Na+) 704.1800 found 704.2403.
Eu(III)-TzMorph2DO3A 
Eu(OTf)3 (108mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H39N9O8Eu (M + H+) 746.2135 found 746.1978.
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La(III)-TzMorph2DO3A 
La(OTf)3 (103mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H38N9O8LaNa (M + Na+) 754.1805 found 754.1914. 
2.2.3 - Metal complexes with TzMorph2DO3A 
All the complexes have been synthesised following the same procedure. 
TzMorph2DO3A (0.100g, 0.17mmol) were dissolved in water (~3mL), the pH of the 
solution corrected to reach pH 7, adding a solution of 1M NaOH. The metal salt was 
dissolved in water (~2mL) and added to the ligand solution. The solution was heated at 
40-50°C for five minutes and then cooled to room temperature. The mixture was purified 
by a short flash column chromatography, getting a clear solution. 
Cu(II)-TzMorph2DO3A 
Cu(OTf)2 (64mg, 0.18mmol) was dissolved in water, obtaining a dark blue solution. 
MS (HR ES-) calc. for C25H38N9O8Cu (M - H+) 655.2140 found 655.1956.
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Mn(III)-TzMorph2DO3A 
MnCl2 (23mg, 0.18mmol) was dissolved in water, obtaining a pale pink-colourless 
solution. MS (HR ES-) calc. for C25H38N9O8Mn (M - H+) 647.2224 found 647.2164. 
Ni(II)-TzMorph2DO3A 
NiCl2*6H2O (42mg, 0.18mmol) was dissolved in water, obtaining a purple solution. MS 
(HR ES-) calc. for C25H38N9O8Ni (M - H+) 650.2197 found 650.2209. 
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La(III)-TzMorph2DO3A 
La(OTf)3 (103mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H39N9O8La (M + H+) 732.1986 found 732.0903. 
Y(III)-TzMorph2DO3A 
Y(OTf)3 (97mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H39N9O8Y (M + H+) 682.1981 found 682.2074.
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Eu(III)-TzMorph2DO3A 
Eu(OTf)3 (108mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H39N9O8Eu (M + H+) 746.2135 found 746.2148.
Gd(III)-TzMorph2DO3A 
Gd(OTf)3 (109mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C25H39N9O8Gd (M + H+) 751.2163 found 751.2228.
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VO(II)-TzMorph2DO3A 
VOSO4*xH2O (29mg, 0.18mmol) was dissolved in water, obtaining a green solution. MS 
(HR ES-) calc. for C25H38N9O9V (M - H+) 659.2233 found 659.2238.
Co(II)-TzMorph2DO3A 
Co(NO3)2*6H2O (53mg, 0.18mmol) was dissolved in water, obtaining a pink solution. MS 
(HR ES-) calc. for C25H38N9O8Co (M - H+) 651.2176 found 651.2234.
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Ce(III)-TzMorph2DO3A 
Ce(NO3)3*6H2O (77mg, 0.18mmol) was dissolved in water, obtaining a colourless 
solution. MS (HR ES+) calc. for C25H38N9O8CeNa (M + Na+) 755.1796 found 755.1584.
Yb(III)-TzMorph2DO3A 
YbCl3*6H2O (69mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR ES+) calc. for C25H38N9O8Yb (M + H+) 767.2345 found 767.2401.
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Lu(III)-TzMorph2DO3A 
LuCl3*6H2O (69mg, 0.18mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR ES+) calc. for C25H38N9O8Lu (M + H+) 768.2348 found 768.2506.
2,4-Dichloro-6-(piperidin-1-yl)-1,3,5-triazine (TzPipCl2)
The compound was prepared based on a modified literature method.[3] Cyanuric chloride 
(10g, 54.2mmol) was dissolved in acetone (30mL), mixture of piperidine (4.61g, 
54.2mmol) and K2CO3 (7.87g, 56.9mmol) in water (70mL) was slowly added dropwise at 
-10°C. After the addition, the reaction was allowed to stir at room temperature for 1h. 
The precipitate was filtered off and washed with water until the pH 7. The white solid was 
dried in vacuo (10.74g, 46.1mmol, 85%). 1H NMR (400 MHz, CDCl3, ppm) δH: 1.01 –
1.18 (m, 6H), 3.16 – 3.29 (m, 4H). 
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2,2’-((4-Chloro-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)azanediyl)diethanol 
(TzPipDEACl) 
TzPipCl2 (5g, 21.4mmol) was dissolved in acetone (50mL) and added to water (50mL) 
to form a slurry. Diethanolamine (2.26g, 21.4mmol) was dissolved in acetone (50mL) 
and added dropwise to the stirred mixture. Sodium bicarbonate (1.81g, 21.4mmol) was 
added portion wise so as to keep the pH neutral. The mixture was left under stirring at 
room temperature for 18 hours. The white solid was filtered off and dried in vacuo (3.00g, 
1.0mmol, 46%). 1H NMR (400 MHz, CDCl3, ppm) δH: 1.55 – 17.1 (m, 8H), 3.68 – 3.91 
(m, 10H).
tert-butyl 2,2',2''-(10-(4-(bis(2-hydroxyethyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-
2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (TzPipDEA-DO3A) 
DO3A (1.00g, 1.68mmol), TzPipDEACl (0.506g, 1.68mmol) and K2CO3 (0.464g, 
3.36mmol) were mixed in dry acetonitrile (40mL) under and atmosphere of nitrogen. The 
mixture was refluxed for three days. Then the mixture was cooled to room temperature 
and the solvent removed. The residue was dissolved in chloroform and washed with 
water, dried over MgSO4 and finally the solvent removed in vacuo (1.00g, 1.28mmol, 
76%). 1H NMR (400 MHz, CDCl3, ppm) δH: 1.43-1.44 (m, 27H), 1.47-1.56 (m, 6H), 
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1.58-1.72 (m, 2H), 2.62-2.89 (m, 6H), 2.90-3.16 (m, 6H), 3.17-3.56 (m, 8H), 3.57-3.97 
(m, 12H); MS (HR ES+) calc. for C38H70N9O8 (M + H+) 780.5347 found 780.5366.  
2,2',2''-(10-(4-(bis(2-hydroxyethyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (TzPipDEA-DO3A)
TzPipDEA-DO3A (1.00g, 1.28mmol) was dissolved in dichloromethane (20mL) and 
trifluoroacetic acid (5.85g, 51.31mmol) was added. The solution was stirred at room 
temperature for 48 hours, obtaining a yellow-brown solution. The solvent were removed 
in vacuo, and the residue solid was dissolved in methanol (~10mL), this was repeated at 
least three times, yielding an off pale brown oil. The oil was treated with Et2O, yielding a 
white solid (0.710g, 1.16mmol, 90%). 1H NMR (400 MHz, D2O, ppm) δH: 1.35 - 1.68 (br 
m, 8H), 2.87 – 4.11 (br m, 32H); 13C NMR (100 MHz, DMSO-d6 ppm) δC: 172.55, 170.27, 
168.72, 165.67, 164.60, 163.93, 158.98, 118.14, 59.56, 58.34, 53.93, 52.95, 52.13, 
51.08, 48.76, 47.14, 45.91, 44.95, 44.15, 37.90, 34.94, 25.78, 24.82, 24.45, 23.85, 21.82; 
MS (HR ES+) calc. for C26H46N9O8 (M + H+) 612.3469 found 612.3474. IR (max, cm−1) 
3117 (s), 3012 (s), 2358 (s), 2249 (s), 1593 (s), 1438 (s), 1035 (s), 921 (s), 896 (s), 883 
(s), 867 (s), 850 (s), 821 (s), 804 (s), 781 (s), 765 (s), 736 (s), 717 (s), 702 (s), 682 (s), 
653 (s), 636 (s), 617 (s). 
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2.2.4 - Metal complexes with TzPipDEA-DO3A 
All the complexes have been synthesised following the same procedure. 
TzPipDEA-DO3A (0.100g, 0.16mmol) were dissolved in water (~3mL), the pH of the 
solution corrected to reach pH 7, adding a solution of 1M NaOH. The metal salt was 
dissolved in water or MeOH (~2mL) and added to the ligand solution. The solution was 
heated at 40-50°C for five minutes and then cooled to room temperature. The mixture 
was purified by a short flash column chromatography, getting a clear solution. 
Cu(II)-TzPipDEA-DO3A 
Cu(OTf)2 (62mg, 0.17mmol) was dissolved in water, obtaining a dark blue solution. 
MS (HR ES+) calc. for C26H45N9O8Cu (M + H+) 673.2609 found 673.2620.
Mn(III)-TzPipDEA-DO3A 
MnCl2*4H2O (34mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR ES+) calc. for C26H43N9O8MnNa (M + Na+) 687.2513 found 687.1889. 
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Eu(III)-TzPipDEA-DO3A
Eu(OTf)3 (103mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C26H43N9O8Eu (M + H+) 762.2448 found 762.1774.  
Y(III)-TzPipDEA-DO3A 
Y(OTf)3 (92mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C26H42N9O8Y (M + H+) 698.2293 found 698.2293. 
Gd(III)-TzPipDEA-DO3A 
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Gd(OTf)3 (104mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C26H43N9O8Gd (M + H+) 767.2397 found 767.2482. 
VO(II)-TzPipDEA-DO3A 
VOSO4*xH2O (28mg, 0.17mmol) was dissolved in water, obtaining a green solution. MS 
(HR ES+) calc. for C26H44N9O9V (M + H+) 677.2702 found 677.2687.
La(III)-TzPipDEA-DO3A 
La(OTf)3 (101mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. MS 
(HR ES+) calc. for C26H43N9O8La (M + H+) 748.2300 found 748.1564. 
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Ca(II)-TzPipDEA-DO3A 
CaCl2*2H2O (26mg, 0.17mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR ES+) calc. for C26H43N9O8Ca (M + H+) 649.2901 found 649.1355. 
2.2.5 - Benzothiale ligands and complexes
2-(4-bromophenyl)-1,3-benzothiazole
The compound was prepared by literature methodology.[4] 2-aminothiophenol (1.03g, 
8.22mmol) and 4-bromobenzaldehyde (1.50g, 8.22mmol) were dissolved in DMSO 
(20mL) and heated at 200°C for three hours. The mixture was cooled to room 
temperature and left under stirring overnight. To the mixture was added water, obtaining 
a precipitate. The solid was filtered and then recrystallised in a solution of acetic acid - 
water (1:4), filtered again and washed with a solution of NaHCO3. The residue was 
recrystallised in hot ethanol and then cooled to room temperature to be filtered (1.97g, 
6.82mmol, 83%). 1H NMR (400 MHz, DMSO-d6, ppm) δH: 7.47 (t, 1H, J = 7.4Hz, -
CHCHCS-), 7.55 (t, 1H, J = 7.5Hz, -CHCHCN-), 7.76 (d, 2H, J = 8.4Hz, -CHCHCBr), 
8.02 (d, 2H, J = 8.4Hz, -CHCHBr), 8.06 (d, 1H, J = 8.1Hz, -CHCS-), 8.14 (d, 1H, J = 
7.9Hz, -CHCN-); MS (HR EI+) calc. for C13H8BrNS (M+) 288.9561 found 288.9347.
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2-(4-phenol)-1,3-benzothiazole
The compound was prepared by literature methodology.[4] 2-aminothiophenol (1.54g, 
12.2mmol) and 4-hydroxybenzaldehyde (1.50g, 12.2mmol) were dissolved in ethanol 
(20mL) and refluxed for 24 hours. The mixture was cooled to room temperature and 
added water, obtaining a precipitate. The solid was filtered and then recrystallised in hot 
ethanol and then cooled to room temperature to be filtered (1.89g, 8.32mmol, 68%). 1H 
NMR (400 MHz, acetone-d6, ppm) δH: 7.02 (d, 2H, J = 8.8Hz, -CHCHCOH), 7.41 (t, 1H, 
J = 8.0Hz, -CHCHCS-), 7.51 (t, 1H, J = 7.6Hz, -CHCHCN-), 7.98 (d, 1H, J = 7.8Hz, -
CHCS-), 8.00 (d, 1H, J = 2.1Hz, -CHCHCOH), 8.02 (d, 1H, J = 2.1Hz, -CHCHCOH), 8.04 
(d, 1H, J = 7.4Hz, -CHCN-), 9.37 (br s, 1H, -OH), ; MS (LR EI+) calc. for C13H9NOS (M+) 
227.04 found 227.04.
2-(4-fluorophenyl)-1,3-benzothiazole
The compound was prepared by literature methodology.[4] 2-aminothiophenol (2.33g, 
18.6mmol) and 4-fluorobenzaldehyde (2.31g, 18.6mmol) were dissolved in ethanol 
(20mL) and refluxed for 24 hours. The mixture was cooled to room temperature and 
added water, obtaining a precipitate. The solid was filtered and then recrystallised in hot 
ethanol and then cooled to room temperature to be filtered (0.814g, 3.55mmol, 19%). 1H 
NMR (400 MHz, acetone-d6, ppm) δH: 7.36 (m, 2H, -CHCHCF), 7.47 (t, 1H, J = 7.2Hz, -
CHCHCS-), 7.56 (t, 1H, J = 8.0Hz, -CHCHCN-), 8.05 (d, 1H, J = 8.1Hz, -CHCS-), 8.10 
(d, 1H, J = 7.9Hz, -CHCN-), 8.21 (m, 2H, -CHCHCF); MS (LR EI+) calc. for C13H9FNS 
(M+) 229.03 found 229.03.
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2-(4-amino)-1,3-benzothiazole
The compound was prepared by literature methodology.[4] 2-aminothiophenol (0.913g, 
7.29mmol) and 4-aminobenzoic acid (1.00g, 7.29mmol) were added at polyphosphoric 
acid (~30mL). The mixture was heated to 180°C for five hours, turning the mixture in a 
green-black solution. The reaction was cooled down to room temperature and 
neutralised with a solution of 10% Na2CO3; the yellow solid was filtered off and dried in 
vacuo (1.24g, 5.49mmol, 75%). 1H NMR (400 MHz, DMSO-d6, ppm) δH: 5.93 (s, 2H, -
NH), 6.66 (d, 2H, J = 8.6Hz, -CHCHCNH-), 7.34 (t, 1H, J = 7.0Hz, -CHCHCS-), 7.45 (t, 
1H, J = 7.1Hz, -CHCHCN-), 7.76 (d, 2H, J = 8.6Hz, -CHCHCNH-), 7.89 (d, 1H, -
CHCHCS), 8.02 (d, 1H, -CHCHCN); MS (LR EI+) calc. for C13H9N2S (M+) 226.06 found 
226.04.
N-(4-(benzo[d]thiazol-2-yl)phenyl)-2-chloroacetamide
The compound was prepared by literature methodology.[5] 2-(4-amino)-1,3-
benzothiazole (2.10g, 9.29mmol) was dissolved in dry dichloromethane, to the mixture 
was added Et3N (0.188g, 1.86mmol) to obtain an homogeneous solution. Chloroacetyl 
chloride (1.58g, 13.93mmol) was dissolved in dichloromethane and added dropwise to 
the solution at 0°C. The reaction mixture was stirred at 0°C for one hour and then was 
stirred further for 24 hours at room temperature. The completion of the reaction was 
monitored by TLC (DCM : MeOH, 8:2). The solid was filtered off and dried in vacuo
(2.05g, 6.77mmol, 73%). 1H NMR (400 MHz, DMSO-d6, ppm) δH: 4.34 (s, 2H, -CCHCl), 
7.44 (t, 1H, J = 7.0Hz, -CHCHCS-), 7.53 (t, 1H, J = 7.0Hz, -CHCHCN-), 7.82 (d, 2H, J = 
8.8Hz, -CHCHCNH-), 8.03 (d, 1H, J = 7.7Hz, -CHCHCS-), 8.08 (d, 2H, J = 8.7Hz, -
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CHCHCNH-), 8.14 (d, 1H, J = 7.9Hz, -CHCHCN-), 10.83 (s, 1H, -CNHCO-); MS (LR ES+) 
calc. for C15H11N2OS (M + H+) 302.02 found 303.07.
N-Benzothiazole-2-yl-succinamic acid
The compound was prepared by literature methodology.[6] 2-(4-amino)-1,3-
benzothiazole (0.300g, 1.33mmol) and succinic anhydride (1.33g, 13.29mmol) were 
refluxed in dry THF (20mL) for 24 hours. The solvent was removed and the solid 
recrystallised with water, filtered off and dried in vacuo (0.200g, 0.61mmol, 46%). 1H 
NMR (400 MHz, DMSO-d6, ppm) δH: 1.56 (d, 2H, J = 6.0Hz, -CCHCH-), 1.62 (d, 2H, J 
= 6.2Hz, -CCHCH-), 6.45 (t, 1H, J = 7.6Hz, -CHCHCS-), 6.54 (t, 1H, J = 7.7Hz, -
CHCHCN-), 6.80 (d, 2H, J = 8.6Hz, -CHCHCNH-), 7.04 (m, 3H, -CHCHCNH- and -
CHCHCS-), 7.12 (d, 1H, J = 8.0Hz, -CHCHCN-), 9.36 (s, 1H, -CNHCO-); MS (LR ES+) 
calc. for C17H14N2O3S (M + H+) 327.07 found 327.07.
4-(benzo[d]thiazol-2-yl)-N-methylaniline
The compound was prepared by literature methodology.[4] 2-aminothiophenol (1.24g, 
9.90mmol) and 4-(methylamino)benzoic acid (1.50g, 9.90mmol) were added at 
polyphosphoric acid (~30mL). The mixture was heated to 180°C for five hours, turning 
the mixture in a green-black solution. The reaction was cooled down to room temperature 
and neutralised with a solution of 10% Na2CO3; the yellow solid was filtered off and dried 
in vacuo (2.06g, 8.58mmol, 87%). 1H NMR (400 MHz, acetone-d6, ppm) δH: 2.85 (d, 3H, 
J = 5.0Hz, -NCH), 5.78 (br, 1H, -NHCH-), 6.73-6.67 (m, 2H, -CHCHCNH-), 7.35 – 7.30 
(m, 1H, -CHCHCS-),7.44 (t, 1H, J = 8.2Hz, -CHCHCN-), 7.91 – 7.86 (m, 3H), 7.95 (d, 
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1H, J = 7.9Hz, -CHCHCN); MS (LR ES+) calc. for C14H12N2S (M + H+) 241.06 found 
241.07.
4-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-4-oxobutanoic acid
4-(benzo[d]thiazol-2-yl)-N-methylaniline (1.00g, 4.17mmol) and succinic anhydride 
(0.500g, 5.00mmol) were refluxed in dry THF (30mL) for 24 hours. The solvent was 
removed and the solid recrystallised with water, filtered off and dried in vacuo (1.26g, 
3.71mmol, 89%). 1H NMR (400 MHz, D2O, ppm) δH: 2.19 (br d, 4H, -CCHCHC-), 2.97 
(s, 3H, -CNCH-), 6.93 (m, 3H), 7.15 (t, 1H, J = 7.7Hz, -CHCHCN-), 7.23 (d, 1H, J = 7.9Hz, 
-CHCHCS-), 7.30 (d, 2H, -CHCHCNH-), 7.57 (d, 1H, J = 8.2Hz, -CHCHCN-); 13C NMR 
(100 MHz, MeOD-d4 ppm) δC: 177.30, 174.42, 169.32, 155.01, 147.67, 136.37, 134.20, 
130.27, 129.67, 128.40, 127.44, 124.09, 123.48, 50.07, 38.36, 30.61, 30.38; MS (LR 
ES+) calc. for C18H16N2O3S (M + H+) 340.07 found 341.10; IR (max, cm−1) 2960 (br), 
1718 (s), 1625 (s), 1599 (s), 1517 (s), 1483 (s), 1452 (w), 1425 (w), 1386 (s), 1336 (w), 
1313 (s), 1249 (w), 1224 (w), 1182 (s), 1122 (s), 1109 (s), 1012 (s), 968 (s), 939 (w), 902 
(w), 850 (s), 825 (s), 760 (s), 729 (s), 682 (w), 623 (s), 567 (s), 516 (w), 443 (s). 
2-(2-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-2-oxoethoxy)acetic acid 
4-(benzo[d]thiazol-2-yl)-N-methylaniline (1.06g, 4.42mmol) and diglycolic anhydride 
(0.634g, 5.46mmol) were refluxed in dry THF (30mL) for 24 hours. The solvent was 
removed and the solid recrystallised with water, filtered off and dried in vacuo (1.01g, 
2.84mmol, 64%). 1H NMR (400 MHz, D2O, ppm) δH: 3.00 (s, 3H, -CNCH), 3.87 – 3.63 
(m, 4H), 6.94 (d, 2H, J = 8.2Hz, -CCHCH-), 7.02 (br m, 1H, -CHCHCS-), 7.20 (t, 1H, J = 
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7.2Hz, -CHCHCN-), 7.35 (br m, 3H), 7.60 (d, 2H, J = 8.2Hz, -CHCHCN-); 13C NMR (100 
MHz, DMSO-d6 ppm) δC: 171.82, 168.71, 166.80, 154.41, 135.09, 129.16, 128.70, 
128.02, 127.21, 126.12, 124.75, 123.43, 122.21, 111.95, 68.93, 67.93, 37.03, 29.76; MS 
(LR AP+) calc. for C18H16N2O4S (M + H+) 356.07 found 357.16; IR (max, cm−1) 3520 (s), 
3475 (s), 3311 (s), 3201 (s), 2960 (s), 2679 (s), 2627 (s), 2400 (s), 2360 (s), 2243 (s), 
1934 (s), 1703 (s), 1516 (s), 1460 (s), 1249 (s), 1143 (s), 765 (s), 738 (s), 717 (s), 694 
(s), 678 (s), 653 (s), 636 (s). 
1-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-3-chloropropan-2-ol 
4-(benzo[d]thiazol-2-yl)-N-methylaniline (1.00g, 4.17mmol) and epichlorohydrin (1.92g, 
20.83mmol) were dissolved in ethanol (30mL) under nitrogen. The solution was refluxed 
for three days. The solvent was removed in vacuo as well the excess of epichlorohydrin. 
The solid was purified by chromatography column (DCM : MeOH, 98 : 2), (750mg, 
2.26mmol, 54%). 1H NMR (400 MHz, DMSO-d6, ppm) δH: 3.06 (s, 3H, -CNCH), 3.45 –
3.39 (m, 1H), 3.73 – 3.56 (m, 3H), 3.97 (br m, 1H), 6.85 (d, 2H, J = 8.7Hz, -CCHCH-), 
7.36 (t, 1H, J = 7.6Hz, -CHCHCS-), 7.47 (t, 1H, J = 7.7Hz, -CHCHCN-), 7.88 (d, 2H, J = 
8.6Hz, -CCHCH-), 7.92 (d, 1H, J = 8.2Hz, -CHCHCS-), 8.04 (d, 2H, J = 7.9Hz, -
CHCHCN-). 13C NMR (125 MHz, DMSO-d6, ppm) δC: 168.3, 154.4, 151.7, 129.0, 126.8, 
124.9, 122.4, 122.3, 121.4, 112.0, 69.2, 55.7, 47.8, 39.8. MS (HR ES+) calc. for 
C17H18ClN2OS (M + H+) 332.0828 found 332.0829; IR (max, cm−1) 3203 (s), 3111 (s), 
3049 (s), 2920 (s), 2754 (s), 2630 (s), 2520 (w), 2372 (s), 2102 (s), 1633 (s), 1510 (s), 
1458 (s), 1396 (s), 1251 (s), 1145 (s), 1099 (s), 910 (s), 867 (s), 850 (s), 788 (s), 758 (s), 
738 (s), 719 (s), 702 (s), 682 (s), 657 (s).
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4-(benzo[d]thiazol-2-yl)-N-methyl-N-(oxiran-2-ylmethyl)aniline (Bz-epox)
1-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-3-chloropropan-2-ol (1.54g, 4.64mmol) 
was dissolved in MeOH (20mL) under nitrogen and then K2CO3 (961mg, 6.96mmol) was 
added to the solution. The mixture was left under stirring for one hour. The mixture was 
diluted with Et2O and washed with water. The aqueous phase was extracted with Et2O 
and the organic layers washed with brine, dried with MgSO4, filtered and the solvent 
removed in vacuo (847mg, 2.86mmol, 62%). 1H NMR (400 MHz, CDCl3, ppm) δH: 2.59 
– 2.55 (m, 1H), 2.82 (m, 1H), 3.10 (s, 3H, -CNCH), 3.19  (s, 1H), 3.49 (dd, 1H, J = 
15.5Hz), 3.78 (d m, 1H, J = 16.0Hz), 6.80 (d, 2H, J = 7.7Hz, -CCHCH-), 7.33 (t, 1H, J = 
7.6Hz, -CHCHCS-), 7.45 (t, 1H, J = 7.6Hz, -CHCHCN-), 7.84 (d, 1H, J = 
7.8Hz, -CHCHCS-), 8.00 (d, 2H, J = 8.1Hz, -CCHCH-), 8.03 (d, 1H, J = 8.1Hz, -
CHCHCN-). 13C NMR (125 MHz, CDCl3, ppm) δC: 167.7, 159.3, 150.5, 128.2, 125.4, 
125.2, 123.5, 121.0, 120.6, 120.4 110.8, 52.6, 49.3, 44.0, 38.2, 29.3, 28.7. MS (HR EI+) 
calc. for C17H16N2OS (M) 296.0983 found 296.0981; IR (max, cm−1) 3203 (s), 3116 (s), 
3053 (s), 2958 (s), 2860 (s), 2748 (s), 2634 (s), 2490 (s), 2382 (s), 2245 (s), 2011 (s), 
1921 (w), 1874 (w), 1803 (w), 1699 (w), 1633 (w), 1519 (w), 1456 (s), 1382 (s), 1246 (s), 
1105 (s), 1004 (s), 983 (s), 867 (s), 846 (s), 821 (s), 802 (s), 788 (s), 765 (s), 758 (s), 
734 (s), 719 (s), 704 (s), 680 (s), 651 (s). 
tert-butyl 2,2',2''-(10-(3-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-2-
hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
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DO3A*HBr (500mg, 0.84mmol) was stirred in acetonitrile (15mL) with K2CO3 (174mg, 
1.26mmol) for 24 hours. The mixture was filtered off and the solvent was removed in 
vacuo. The residue was dissolved in EtOH (25mL), Et3N (0.084g, 0.83mmol) and 
Bz-epox (0.246g, 0.83mmol) were added to the solution. The solution was heated at 
50-60°C for 24 hours. The solution was cooled to room temperature and the solvent and 
the Et3N removed in vacuo (0.600g, 0.74mmol, 89%). 1H NMR (400 MHz, CDCl3, ppm) 
δH: 1.45 (br s, 27H, tBuO-), 4.02 – 2.49 (br m, 30H), 6.92 – 6.66 (m, 2H, -CCHCH-), 7.33 
– 7.28 (m, 1H, -CHCHCS-), 7.43 (t, 1H, J = 7.5Hz, -CHCHCN-), 7.84 (d, 1H, J = 7.4Hz, 
-CHCHCS-), 8.18 – 7.87 (m, 3H). MS (HR ES+) calc. for C43H67N6O7S (M + H+) 811.4792 
found 811.4802. 
2,2',2''-(10-(3-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-2-hydroxypropyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Bz-epox-DO3A) 
tert-butyl 2,2',2''-(10-(3-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-2-hydroxypropyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (0.600g, 0.74mmol) was dissolved 
in dichloromethane (15mL) and trifluoroacetic acid (2.53g, 22.21mmol) was added. The 
solution was stirred at room temperature for 48 hours. The solvent were removed in 
vacuo, and the residue solid was dissolved in methanol (~10mL), this was repeated at 
least three times. The oil was treated with Et2O, yielding an off dark green hygroscopic 
oil (0.428g, 0.66mmol, 90%). 1H NMR (400 MHz, MeOD-d4, ppm) δH: 2.60 – 3.28 (br m, 
12H), 3.37 – 4.52 (br m, 18H), 6.96 (d, 2H, J = 7.7Hz, -CCHCH-), 7.37 – 7.43 (m, 1H, -
CHCHCS-), 7.52 (t, 1H, J = 7.1Hz, -CHCHCN-), 7.90 (d, 1H, J = 8.0Hz, -CHCHCS-), 
7.95 (d, 1H, J = 7.8Hz -CHCHCN-); 13C NMR (100 MHz, MeOD-d4, ppm) δC: 173.3, 
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169.8, 128.7, 126.3, 124.6, 121.5, 120.9, 111.9, 111.7, 65.5, 55.9, 55.0, 52.6, 52.3, 51.8, 
50.4, 49.4, 48.5, 42.0, 38.5, 14.0. MS (HR ES+) calc. for C31H43N6O7S (M + H+) 643.2914 
found 643.2897. IR (max, cm−1) 3198 (s), 2895 (s), 2368 (w), 2266 (w), 1597 (s), 1514 
(s), 1441 (w), 883 (s), 846 (s), 821 (s), 806 (w), 787 (s), 765 (s), 758 (s), 738 (s), 721 (s), 
702 (s), 680 (s). 
2.2.6 - Metal complexes with Bz-epox-DO3A 
All the complexes have been synthesised following the same procedure. 
Bz-epox-DO3A (0.050g, 0.08mmol) were dissolved in a mix of water and methanol 
(~3mL), the pH of the solution corrected to reach pH 7, adding a solution of 1M NaOH. 
The metal salt was dissolved in water (~2mL) and added to the ligand solution. The 
solution was heated at 40-50°C for five minutes and then cooled to room temperature. 
The mixture was purified by a short flash column chromatography, getting a clear 
solution. 
Cu(II)-Bz-epox-DO3A 
CuSO4*5H2O (21mg, 0.08mmol) was dissolved in water, obtaining a dark blue solution. 
MS (HR AP+) calc. for C31H41N6O7SCu (M + H+) 704.2053 found 704.2056.
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Tb(III)-Bz-epox-DO3A 
Tb(OTf)3 (50mg, 0.08mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR AP+) calc. for C31H41N6O7STb (M + H+) 799.1933 found 799.1933.
Eu(III)-Bz-epox-DO3A 
Eu(OTf)3 (49mg, 0.08mmol) was dissolved in water, obtaining a colourless solution. 
MS (HR AP+) calc. for C31H41N6O7SEu (M + H+) 791.1878 found 791.1873.
VO(II)-Bz-epox-DO3A 
VOSO4*xH2O (15mg, 0.08mmol) was dissolved in water, obtaining a blue solution. 
MS (HR ES-) calc. for C31H39N6O8SV (M - H-) 706.1990 found 706.2006.
57 
DFO-Ga(III) complex 
Deferoxamine mesylate (0.100g, 0.15mmol) was dissolved in water (~5mL), KHCO3
(0.061g, 0.61mmol) and Ga(NO3)3*xH2O (0.039g, 0.15mmol) were added to the solution 
and left under stirring for 24 hours. The solvent was removed in vacuo. MS (HR ES+) 
calc. for C25H46N6O8Ga (M + H+) 627.2633 found 627.2656. 
DFO-Ga(III)-Bz-epox 
To the mixture obtained from DFO-Ga (0.100g, 0.15mmol of deferoxamine mesylate), 
Bz-epox (0.046g, 0.15mmol) and Et3N (0.015g, 0.15mmol) were added to the white 
mixture and stirred at ~50°C for 48 hours. The mixture was cooled to room temperature 
and the solid filtered off. The solvent was finally removed in vacuo. (0.120g, 0.13mmol, 
85%).1H NMR (400 MHz, DMSO-d6, ppm) δH: 1.14 – 2.40 (br m, 27H), 2.58 – 3.73 (br 
m, 26H), 6.84 (d, 2H, J = 9.0Hz, -CCHCH-), 7.34 (t, 1H, J = 7.7Hz -CHCHCS-), 7.45 (t, 
1H, J = 7.7Hz, -CHCHCN-), 7.90 (m, 3H), 8.03 (d, 1H, J = 6.8Hz -CHCHCN-); 13C NMR 
(100 MHz, DMSO-d6, ppm) δC: 154.4, 134.2, 128.9, 122.2, 112.0, 58.8, 28.5, 8.5. MS 
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(HR ES+) calc. for C42H62N8O9SGa (M + H+) 923.3616 found 923.3653. IR (max, cm−1) 
3305 (w), 3203 (w), 3117 (w), 2945 (w), 2870 (w), 2513 (w), 2378 (w), 1516 (w), 1458 
(w), 977 (s), 947 (s), 906 (s), 883 (s), 864 (s), 846 (s), 821 (s), 806 (s), 785 (s), 758 (s), 
736 (s), 713 (s), 700 (s), 679 (s), 655 (s), 640 (s), 619 (s). 
DFO-Eu(III) complex 
Deferoxamine mesylate (0.100g, 0.15mmol) was dissolved in water (~5mL), KHCO3
(0.061g, 0.61mmol) and Eu(OTf)3 (0.091g, 0.15mmol) were added to the solution and 
left under stirring for 24 hours. The solvent was removed in vacuo. MS (HR ES+) calc. 
for C25H46N6O8Eu (M + H+) 709.2576 found 709.2581. 
DFO-Eu(III)-Bz-epox 
To the mixture obtained from DFO-Eu (0.100g, 0.15mmol of deferoxamine mesylate), 
Bz-epox (0.046g, 0.15mmol) and Et3N (0.015g, 0.15mmol) were added to the white 
mixture and stirred at  ~50°C for 48 hours. The mixture was cooled to room temperature 
and the solid filtered off. The solvent was finally removed in vacuo. (0.130g, 0.13mmol, 
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85%). MS (HR ES+) calc. for C42H62N8O9SEu (M + H+) 1005.3559 found 1005.3596. IR 
(max, cm−1) 2515 (w), 2058 (w), 1271 (w), 883 (s), 842 (s), 817 (s), 804 (s), 788 (s), 779 
(s), 765 (s), 758 (s), 719 (s), 702 (s), 680 (s), 665 (s), 651 (s). 
DFO-Traut's reagent 
The compound was prepared by literature methodology.[7] Deferoxamine mesylate 
(0.300g, 0.46mmol) was dissolved in phosphate buffered saline solution (50mL) adjusted 
at pH 8.0 and 2-iminothiolane hydrochloride (0.126g, 0.92mmol) was added. The 
reaction was left under stirring for six hours. After the pH was changed to 5, adding small 
amounts of 0.1M HNO3. The solution was then extracted with three portions of 1-butanol 
(~60mL total). The organic fractions were reunited and washed with brine, and then dried 
on MgSO4. The solvent was removed in vacuo. The residue was then dissolved again in 
1-butanol, eliminated once again and then the residue finally suspended in a mixture 
(1:1) of DCM and MeOH. Undissolved inorganic salts were filtered off and the solvent 
finally removed in vacuo, obtaining a brown oil, the oil was recrystalised with Et2O and 
then the solvent removed again in vacuo, obtaining a brown solid (0.250g, 0.38mmol, 
83%).1H NMR (400 MHz, MeOD-d4, ppm) δH: 1.41 – 1.24 (m, 10H), 1.54 – 1.41 (m, 9H), 
1.55 – 1.71 (m, 5H), 1.73 – 2.17 (m, 4H), 1.73 – 2.17 (m, 4H), 2.20 – 2.67 (m, 5H), 2.68 
– 2.96 (m, 3H), 3.09 – 3.25 (m, 4H), 3.25 – 3.45 (m, 3H), 3.53 – 3.68 (m, 5H); 13C NMR 
(100 MHz, MeOD-d4, ppm) δC: 173.2, 172.1, 65.4, 61.3, 51.5, 48.5, 40.8, 39.3, 39.0, 
37.7, 34.4, 31.7, 31.5, 30.0, 29.8, 29.3, 28.5, 27.7, 27.4, 26.4, 25.9, 25.6, 23.5, 23.3, 
23.1, 23.0, 22.7, 18.9, 18.6, 12.8. MS (HR ES+) calc. for C29H56N7O8S (M + H+) 662.3911 
found 662.3910. IR (max, cm−1) 3238 (w), 3124 (w), 2791 (s), 2534 (s), 2449 (s), 2389 
(s), 2322 (s), 2266 (s), 1978 (w), 1924 (w), 1458 (w), 1178 (w), 779 (s), 758 (s), 738 (s), 
719 (s), 680 (s), 652 (s), 638 (s), 619 (s). 
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1-((4-(benzo[d]thiazol-2-yl)phenyl)(methyl)amino)-3-(1,4,7,10-
tetraazacyclododecan-1-yl)propan-2-ol (cyclen-Bz-epox) 
Cyclen (0.059g, 0.34mmol) was dissolved in acetonitrile (10mL) and Bz-epox (0.100g, 
0.34mmol) was added to the solution with few drops of THF. The mixture was left under 
stirring for three days. The solid was filtered off and the solvent was removed in vacuo. 
(0.139g, 0.30mmol, 88%). 1H NMR (400 MHz, MeOD-d4, ppm) δH: 2.42 – 2.91 (br m, 
21H), 3.07 (s, 3H), 6.75 (d, 2H, J = 9.0Hz, -CCHCH-), 7.25 – 7.31 (m, 1H, -CHCHCS-), 
7.41 (t, 1H, J = 7.1Hz, -CHCHCN-), 7.81 (d, 1H, J = 7.8Hz, -CHCHCS-), 7.87 – 7.99 (m, 
3H); 13C NMR (100 MHz, CDCl3, ppm) δC: 168.7, 154.4, 151.6, 134.5, 129.1, 126.0, 
124.3, 124.2, 122.2, 121.4, 121.3, 112.0, 111.7, 67.6, 65.8, 59.4, 58.1, 56.8, 52.4, 47.1, 
46.1, 45.9, 45.6, 39.6, 31.0, 30.3, 22.7, 18.5, 15.3. MS (HR ES+) calc. for C25H37N6OS 
(M + H+) 469.2750 found 469.2731. IR (max, cm−1) 3306 (w), 3205 (s), 3064 (w), 2956 
(s), 2860 (s), 2376 8s), 1917 (w), 1637 (w), 1516 (w), 1458 (w), 881 (s), 850 (s), 825 (s), 
804 (s), 779 (s), 765 (s), 758 (s), 736 (s), 719 (s), 696 (s), 678 (s), 648 (s). 
Cu(II)-Cyclen-Bz-epox 
Cyclen-Bz-epox (0.030g, 0.06mmol) was dissolved in MeOH (~3mL); a solution of 
CuSO4*5H2O (0.017g, 0.06mmol) was dissolved in MeOH (~2mL) and added to the 
ligand. The solution was heated to 50°C for five minutes, changing colour in a dark blue 
solution. The solution was cooled to room temperature and filtered off on a small 
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chromatography column. MS (HR ES+) calc. for C25H35N6O1SCu (M + H+) 530.1889 
found 530.1894. 
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CHAPTER 3 
1-N-2,4,6-TRIAZINE SUBSTITUTED CYCLEN LIGANDS 
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3.1 - TRIAZINE CORE INTRODUCTION
Many physiological processes, such as immune cell activation, cell migration and cell 
proliferation, require direct contact between cells, or between cells and extracellular 
matrix. These interactions are also involved in the development of tumour metastases,[1] 
tumour cells can break free from the site and can be transferred through the blood or 
lymphatic system to another tissue to invade, then they must be able to develop their 
own blood supply (angiogenesis) to survive and in this way the tumour can be spread to 
different sites.[2] One group molecules responsible for cell adhesion are the integrins. 
Integrins are heterodimeric glycoproteins containing α and β chains; the α chain has 
approximately 1100 amino acids and usually consists of two chains joined by a disulfide 
bond, most of the subunit is an extracellular chain, with a short transmembrane domain 
and a short cytoplasmic domain. The β chain typically has 800 residues and can be 
divided into three broad families.[3] The integrin αVβ3 is one of the most widely studied, 
also known as the vitronectin receptor, is responsible for cells binding to proteins in the 
extracellular matrix (ECM), and has been found to be over expressed in many different 
tumour cells, including osteosarcomas, neuroblastomas, melanomas, breast, brain and 
lung cancer and has a role in angiogenesis process.[4] Thus it is clear that the 
development of αVβ3 recognition species are attractive targets for new imaging or 
therapeutic agents.[5]
 The amino acid sequence Arg-Gly-Asp (RGD), known as "universal cell recognition 
site", is one of the most frequently used integrin binding sequence motifs. The crystal 
structure of the αVβ3 complexed with a cyclo-RGD ligand was resolved by Arnaout's 
group in 2002,[6] and showed that ligation intimately involved the RGD sequence. Hence, 
the development of antagonists based on this sequence can be used to inhibit or, in the 
case of imaging agent development, locate the αVβ3 receptor.
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Cyclo RGD petites are very expensive and already extensively used in imaging 
inflammation,[7] so the current research has focused on the design of alternative 
vectorising agents. 
 Cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) has always received much 
attention due its low cost allowing a wide range of applications to be found.[8] The ability 
to progressively substitute the chloro substituents with a range of groups, through 
sequential nucleophilic aromatic substitution (SNAr) reactions, enables the controlled 
synthesis of mono-, di- and tri-substituted compounds.[8] These have been widely studied 
to create a library of complex ligand structures able to incorporate an ample range of 
functional groups and the capacity to control their physicochemical properties to fit the 
desired purpose.[8] Triazines have also been extensively used as building blocks for 
pesticides and herbicides,[9] and in the manufacture of melamine resins[10] or crosslinking 
agents. 2,4,6-Triazine derivatives have also found extensive medicinal applications as 
antimicrobials,[11] antivirals,[12] antituberculosis drugs,[13] and antimalarials,[14] but most 
extensively as non-proliferative chemotherapeutic (anti-cancer) agents.[15]
Dipyridamole (Persantine©) is used as an antiplatelet drug to prevent strokes, inhibit 
thrombus formation and as a vasodilator (Figure 3.1). It is also an inhibitor of human 
equilibrative nucleoside transporters (hENTs) and its similarity to cyanuric chloride, 
makes it an attractive target for hENT targeting. In the current work the tri-substituted 
triazine moiety is used by incorporating the piperidine and diethanolamine moieties and 
allowing the third chlorine free for further substitution with a metal binding site.
Figure 3.1: the targeting molecule (left) and Dipyridamole (right)
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Present examples of chemotherapeutic agents containing the 1,3,5-triazine core are 
hexamethylmelamine (HMM, Altretamine©) and 2-amino-4-morpholino-s-triazine (Figure 
3.2), both clinically used to treat lung, breast and ovarian cancer.[16] Although the precise 
mechanism by which Altretamine© works is unknown some hypotheses have been 
presented; the most evaluated theory considers the compound as an alkylating 
antineoplastic agent, with the capacity to damage the tumour cells through the production 
of formaldehyde as an alkylating species via oxidative p450 action on the parent drug.[17]
Figure 3.2: HMM (left) and 2-amino-4-morpholino-s-triazine 
Kumar's group also reported a list of di- and tri-substituted s-triazine derivatives with  
anticancer activity.[18] Tri-substituted s-triazine derivatives, bearing anilino, benzoxazole 
and morpholino groups, showed the best activity against the cancer cell lines tested 
compared to the di-substituted s-triazine compounds that do not bear the morpholine, 
revealing the importance of morpholino group. The anticancer activity of morpholino 
group has been proved recently targeting phosphatidylinositol 3-kinase (PI3K) in 
tumours.[19] PI3K has been proved as the key regulator of the cell growth, metabolism 
and survival; the activation of the PI3K pathway in cancerous tissues has encouraged 
interest in identifying potent and selective inhibitors of PI3K pathways.[20] One of the best 
inhibitors currently synthesised is ZSTK474 (Figure 3.3), due to its capacity to bind the 
Val828 by a hydrogen bond of the oxygen of one morpholine and Pro758 by the 
difluoromethyl group.[21] At present, due to its high in vivo activity against human cancer 
xenografts, this compound has entered in clinical trials and is used as the benchmark for 
new molecules.
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Figure 3.3: ZSTK474 compound and analogues 
The triazine structure of the compound makes it ‘editable’ by the use of different 
nucleophiles. Work by Rewcastle's group synthesised different analogues (Figure 3.4) 
and evaluated the binding properties to PI3K and the inhibition of phosphorylation or cell 
growth.[22] Analogues of ZSTK474 can be synthesised for application as new 18F-PET 
probes. The presence of morpholine and difluoromethyl moieties are essential to bind 
PI3K and the possibility to modify the triazine core makes it attractive for imaging probes. 
ZSTK474 derivatives have been synthesised using different approaches by Makino's 
group,[23] the first was to substitute one of the morpholines with a piperazine, leaving a 
reaction point for a further functionalisation. The compound showed a weaker binding 
affinity to the PI3K, revealing how the morpholine promotes the affinity via hydrogen 
bonding. To compensate the loss of stability two more compounds have been 
synthesised, one of them retaining the piperazine core but adding an appropriate 
electron-donating substituent like a hydroxy group at the 4-position of the benzimidazole 
and another, retaining the two morpholines on the triazine and adding a fluoroethyl group 
at the 4-position of the benzimidazole      (Figure 3.4)
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Figure 3.4: compounds synthesised by Makino's group
The stability showed by the second molecule was comparable to the ZSTK474 and made 
it eligible for radiolabeling studies as a PI3K probe. The compound exhibited the rapid 
blood clearance that is one of the important characteristics for tumour imaging probes, 
but unfortunately also a low tracer accumulation was observed. 
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3.2 - SYNTHESIS OF DI-MORPHOLINE TRIAZINE CORE LIGAND 
Morpholines were chosen as a simple model analogues of more complicated species 
(e.g. amino acids), whilst still imparting some water solubility, hydrogen bonding potential 
and affording often crystalline intermediates. Due to the facile sequential displacement 
of its chlorine atoms, cyanuric chloride was used as a core to prepare many compounds, 
by reacting different amino compounds in the presence of base.[8] The replacement of 
the chlorine atoms may be controlled via changes in temperature, where the substitution 
of the first chlorine atom occurs at 0-5°C, the second occurs approximately at room 
temperature and the third requires temperatures at 70-100°C in order to activate the last 
chlorine (Figure 3.5) 
Figure 3.5: general synthesis of mono, bis and tri substituted s-triazines 
The starting material DO3A*HBr was prepared using published method,[24] using the 
macrocycle to coordinate the metal. Before synthesising the dipyridamole analogues and 
to understand better the triazine chemistry a di-morpholine triazine moiety, following the 
preparation reported by Hughes (Cardiff University, PhD thesis, 2012) has been 
synthesised to react with the DO3A core. The protected macrocycle was then reacted 
with 2-4-dimorpholino-s-triazine in acetonitrile under reflux and an inert atmosphere for 
three days, yielding the trisubstituted triazine (TzMorph2DO3A) as a colourless oil. Finally 
the product was dissolved in DCM and deprotected adding TFA and leaving the reaction 
under stirring for two days. The completion of the reaction was followed by 1H NMR by 
the loss of the peaks at 1.43-1.46 ppm, revealing the deprotection of the carboxylic acid 
groups. (Figure 3.6)
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Figure 3.6: synthesis of TzMorph2DO3A ligand 
71 
3.3 - SYNTHESIS OF COMPLEXES
A wide range of metals have been used to explore and understand better the 
coordination chemistry of this ligand. To synthesise the complexes two different 
procedures have applied.  
The first one required that TzMorph2DO3A (0.17mmol) was dissolved in ca. 3mL of water 
and the pH of the solution corrected to reach pH 7, adding a solution of 1M NaOH. The 
metal salt, typically as a chloride, triflate or nitrate, was dissolved in ca. 2mL of water and 
added to the ligand solution. The solution was heated at 40-50°C for five minutes and 
then cooled to room temperature. The mixture was purified by flash chromatography on 
a short column, to afford a clear solution (Figure 3.7). 
Figure 3.7: first method synthesis of TzMorph2DO3A complexes 
In the second method TzMorph2DO3A (0.50mmol) was dissolved in ca. 3mL of MeOH. 
The metal salt was dissolved in ca. 2mL of MeOH and added to the ligand solution. The 
pH of the solution corrected to basic pH adding Et3N until there was the formation of a 
precipitate and the solid was separated by centrifuge (Figure 3.8). 
Figure 3.8: second method synthesis of TzMorph2DO3A complexes 
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All the complexes have been characterised by ESI-MS. Several examples afforded 
crystals suitable for x-ray crystallography. The structures obtained will be reported and 
discussed below. 
Electronic spectroscopy has also been used to determine ligand field parameters. 
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3.4 – SPECTROSCOPY STUDIES
3.4.1 - Determination of the empirical formula 
The last step of the synthesis the ligand TzMorph2DO3A, TFA has been used to remove 
the protection groups; all the successive compounds were prepared assuming that the 
ligand does not present any residual molecule of acid. This ensures that the ligand is 
always used in excess, driving reactions to completion. 
However, it is likely that given the basicity of cyclen TzMorph2DO3A will be initially 
isolated as a TFA salt. To determine the presence of the amount of TFA present and 
hence the empirical formula of the ligand a metal titration was undertaken (Job's 
method). 
Aliquots of 100 μL ligand solution (0.1M) was added to a fixed volume of nickel 
equimolar solution in nine volume ratios and the absorbance of the solutions has been 
recorded. The ratio of the solutions and the absorbance registered at 541 nm are 
reported in the table and the graph below (Figure 3.9) 
 The maximum amount of product is formed when the proportions of reactants 
employed corresponds to the empirical formula. For n = 0 (TzMorph2DO3A-TFAn) a ratio 
of 1:1 would appear at 100 μL added volume (total volume = 200 μL). The data show 
that the maximum absorbance corresponds with the ratio metal : ligand equal to 4 : 6, 
this means that the data is consistent for TzMorph2DO3A-TFAn with n = 3. 
Sample Volume ratio of M : Ligand Absorbance (A) at 541 nm
A 1 :9 0.0689
B 2 : 8 0.1098
C 3 : 7 0.2637
D 4 : 6 0.3096
E 5 : 5 0.2465
F 4 : 6 0.1084
G 3 : 7 0.1683
H 2 : 8 0.0632
I 1 :9 0.0611
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Figure 3.9: UV spectra with different ratios metal : ligand. The blue line represents the sample D, with a 
ratio 4:6. The red line represents the pure Ni(II) spectrum.
3.4.2 - UV measurements 
UV measurements of solution of Cu(II), Co(II) and Ni(II) have been conducted to 
determine the nature of the complexes in solution. To a 0.02 M solution of 
TzMorph2DO3A-TFA3, adjusted at pH 7 adding a solution 2M of NaOH, has been added 
an equimolar solution of the metal and an UV spectrum in the range of 350 - 1300 nm 
has been recorded. The data obtained will be discussed for every metal analysed in the 
below section. 
0.00
0.25
0.50
0.75
1.00
350 450 550 650 750
Ab
so
rb
an
ce
 (A
)
Wavelength  (nm)
D
E
C
G
I
H
F
B
A
75 
3.4.3 - Copper(II)-TzMorph2DO3A
Figure 3.10 - Electronic spectrum of 0.01M Na[Cu-TzMorph2DO3A] in H2O. The sample was prepared 
from TzMorph2DO3A-TFA3 + CuCl2.6H2O after adjusting the pH to 7 with 2M NaOH. 
The electronic spectrum of Na[Cu(TzMorph2DO3A)in H2O is displayed in figure 3.10.  
The Cu(II) complex is assigned as 5 coordinated trigonal bipyrimidal system. This is 
evidenced by the presence of two features at 688 and 1050 nm in the electronic spectrum 
(Figure 3.10). This suggests that this is an N3O2 trigonal bipyrimidal system from three 
cyclen nitrogen and two pendant carboxylate derived donors. From an examination of 
many 4,5, and 6 coordinate complexes,[25] this assignment is in good agreement with 
other 5 coordinate donor compounds. For example Cu(bipy)2OAc (10,860 and 15,150 
cm-1) and Cu(Me6tren)Br2 (10,400 and 13,400 cm-1).[25]
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3.4.4 - Nickel(II)-TzMorph2DO3A
Figure 3.11-  Electronic spectrum of 0.01M Na[Ni-TzMorph2DO3A] in H2O. The sample was prepared from 
TzMorph2DO3A-TFA3 + NiCl2.6H2O after adjusting the pH to 7 with 2M NaOH. 
The electronic spectrum of the Ni(II) complex of TzMorph2DO3A is shown in figure 3.11. 
Here it is apparent that complex is a distorted 6 coordinate species. The low extinction 
coefficient values observed for the transitions are in the range of 6 – 30, indicative the 
origin of these transitions are d – d in nature. However there is clearly an addition feature 
at 540 nm. The bands observed are tentatively assigned in the table below. Analysis of 
this data yields a ligand field splitting value of 8928 cm-1 and a Racah B (B = (ν2 + ν3 - 3 
ν1)/15) parameter of 1010 cm-1. These calculations are of course crude approximations 
since they assume octahedral symmetry, which is unlikely to be attainable in complexes 
of TzMorph2DO3A. The assignment of ν2 as the peak at 624 nm and not 540 nm was 
made on the basis that this affords a Racah B parameter of 1010 cm-1 whilst using the 
540 nm peak would yields a nonsensical value of 1176 cm-1 as it is higher than that of 
the free ion (1042 cm-1). The high Racah B value obtained implies a poorly covalent 
complex with a highly ionic character, logical for an N3O3 chromophore with 3 anionic 
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donors. It is worth noting that the Δo value obtained is only a little higher than that of the 
[Ni(OH2)6]2+ ion (B = 8,500cm-1) and we may assume that the macrocyclic and chelate 
effects account for the stability of the complex The weak, formally forbidden 1E2g  3A2g
transition may be tentatively assigned to the weak feature at 820 nm. However this is 
somewhat speculative due to the difficulty of obtaining a good NIR background in 
aqueous solution. 
It is possible speculate that the additional feature at 540 nm resembles that obtained in 
Lifsshitz salts in which an octahedral-square planar equilibrium or mixture exist.[26] Hence 
the band at 540 nm may be due to a square planar N2O2 component arising from the 
dissociation of two amine and one carboxylate donor in the strained triazine-cyclen 
macrocycle. Given the constraints of the macrocyclic ring in this system it is likely that 
the N-donor and their corresponding carboxylate donors at ring position 4 and 10 are 
those that remain coordinated (the triazine is at ring position 1). 
Transition assignment  (nm)  (cm-1)
1 = 3T2g  3A2g (o) 1120 8928
2 = 3T1g  (F)   3A2g 624 16025
3 = 3T1g  (P)   3A2g 386 25906
Racah B (2 + 3 - 3 1)/15) 1010
Table 1 - Spectral assignemnt of Na[Ni-TzMorph2DO3A] in H2O and associated 
ligand field parameters.
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3.4.5 - Cobalt(II)-TzMorph2DO3A 
Figure 3.12 - Electronic spectrum of 0.01M Na[Co-TzMorph2DO3A] in H2O. The sample was prepared 
from TzMorph2DO3A-TFA3 + CoCl2.6H2O after adjusting the pH to 7 with 2M NaOH. 
The electronic spectrum of Na[Co-TzMorph2DO3A] in H2O is illustrated in figure 3.12. 
The weak nature of the transitions implies that the bands observed are d - d in origin and 
that the complex is a high spin low symmetry d7 (i.e. Co(II)) species. The ground state 
term for high-spin d7 is 4T1g with spin allowed transitions to 4T2g (low energy feature), 4A2g
and 4T1g(P) level (high energy features). Since the complex envelope shape of the higher 
energy feature is indicative of low symmetry and the 4A2g transition is often weak (formally 
a two electron transition) is not possible to rigorously derive, from this data alone, Δ and 
B for this species. However using the method of Lever[27] it could be possible to use the 
transition energy ratio method to approximate Δ and B. Taking ν1 as 1105 nm and ν3 as 
the more intense high energy feature (440 nm) we obtain a Dq/B value of 1.38, ν3/B = 
35.7 and Dq= 1.45 B. Hence it could be possible to approximate Δ = 9090 cm-1 and B = 
660 cm-1.While this Δ value seems reasonable for this type of trianionic ligand, the B 
value is somewhat low in comparison to the d7 free ion at 985 cm-1 or the [Co(OH2)6]2+
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complex at 850 cm-1.[28] This inconsistency may arise from the assumption that this 
complex is octahedral in solution, which given its distorted geometry is unlikely.  
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3.5 – SINGLE CRYSTAL X-RAY STUDIES
3.5.1 – D-BLOCK METAL COMPLEXES OF TZMORPH2DO3A 
3.5.1.2 - Copper(II) and Nickel(II) complexes of TzMorph2DO3A 
Through the vapour diffusion of acetone into water solutions of the Ni(II) and Cu(II) 
complexes of TzMorph2DO3A it has been possible to isolate light blue needle-like 
crystals for the Cu(II) species and light purple long columns for the Ni(II) complex suitable 
for the crystallographic studies.
Their relevant crystal parameters and details of data collection are presented in the 
supporting information.
H[Ni(II)-TzMorph2DO3A] - The data reveal that the nickel compound forms a 1:1 
metal : ligand ratio, with the molecule crystallising in the orthorhombic space group 
Pbc21 (Figure 3.13). The asymmetric unit contains two independent molecules (Z = 2) 
as well as one acetone molecule for complex that gives to the structure a C2 symmetry.
Figure 3.13: H[Ni(II)-TzMorph2DO3A] complex structure
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The metal centre is six coordinate with a geometry resembling a distorted octahedron, 
being the Ni(II) a d8 ion, the structure could suggest that the metal assumes a high spin 
configuration in the solid state. Figure 3.14, to show better the coordination structure the 
triazine core has been removed.
Figure 3.14: H[Ni(II)-TzMorph2DO3A] with triazine core omitted for clarity
The structure also displays an approximate mirror plane through the triazine core, with 
each morpholine group in a pseudo-chair conformation and essentially sp2 geometry at 
the morpholino N atom. The Ni(II) centre is coordinated by all four of the nitrogens in the 
macrocyclic ring while the two remaining coordination sites are occupied by the 4,10-
pendant acid groups adjacent to the triazine ring, leaving the third one, opposite to the 
triazine core, unbound.
Considering the bond length between the metal and the axial nitrogen bearing the non 
bonding acid it is possible to see that it is 2.144(3) Å, longer than the length found for the 
equatorial Ni1 - N1 and Ni1 - N3 bonds, 2.098(3) and 2.103(3) Å respectively. The 
lengths found for these bonds are in accordance with the average trend that can be 
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observed in the Ni octahedral species (Ni - N = 2.07 - 2.11 Å) than in square planar 
species (Ni - N = 1.88 - 1.91 Å).[29] The length of Ni - O bonds was found to be 2.000(3) 
and 2.016(3) Å respectively, shorter than other Ni complexes encountered in literature.[29]
This distance is given by the two acid groups borne on the macrocycle, considering the 
coordination provide by an acetate group is possible to see that the bonds lengths are 
similar to those of the Ni - N bonds better resembling a perfect octahedral geometry.[30]
The stronger distortion observed in the structure can instead be explained by the chelate 
effect of the two acid groups, which constrains the equatorial bonds in a more rigid and 
distorted geometry. [30]
Significantly, the crystal structure also reveals that the Ni - Ntriazine bond to be elongated 
at 2.370(3) Å which is a consequence of the highly electron triazine substituent. As the 
triazine core is very electron deficient, the amine is a relatively poor donor and a weaker 
Ni - N bond results.
H[Cu(II)-TzMorph2DO3A]- The copper (II) complex crystallises in the orthorhombic 
space group Pbca and contains 8 molecules in the unit cell (Z = 8). (Figure 3.15)
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Figure 3.15: H[Cu(II)-TzMorph2DO3A] complex structure (top) and unit cell (bottom)
The copper (II) presents a distorted octahedral N4O2 geometry through the four 
macrocyclic nitrogens and two (opposite) carboxylate arms, while the other carboxylic 
acid group is turned away from the Cu atom. This conformation is not unusual for the 
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copper chemistry, in literature indeed the two most common geometries for a copper 
complex coordinated by cyclen or derivates are the octahedral and the square pyramidal 
geometry. [31]
 As expected for a Cu(II) complex in the octahedral geometry there is a tetragonal 
distortion with four relatively short bonds and two longer bonds; 2.056(3) and 2.090(3) Å 
for the macrocyclic ring and 1.936(2) and 1.942(2) Å for the carboxylate arms involved 
in the coordination and disposed in the equatorial plane; comparable bond distances 
found in the literature.[31e, 32]
 There is no significant difference in the metal - nitrogen bond lengths that not bear 
the carboxylate arm involved in the coordination as well; the length results 2.318(3) Å 
compared to 2.391 and 2.390 Å found in a DO3A - copper complex in literature.[32]
Finally, in a similar manner to the Ni(II) complex the M - Ntriazine distance is the longest 
(2.585(3) Å) and in an axial position, due to the lower electron density at this amine.
 At the supramolecular level it is possible to identify an interesting H-bond 
networking (Figure 3.16). H-bonds can be found between O8 of the morpholine moiety, 
and H9 of the ethanol molecule in the crystal lattice, with a distance of 2.062(3) Å. The 
carboxylate oxygen O2 is also involved in coordination with two molecules of water 
(protons H10A/B) incorporated in the crystal, with a length of 1.917(3) Å. Finally, the 
second carboxylate group O4 directly binds the metal (with a length of 1.722(3) Å),with 
H6 of the carboxylate group in the axial position and therefore not involved in the 
coordination. 
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Figure 3.16: H-bond network in H[Cu(II)-TzMorph2DO3A] complex 
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3.5.1.3 - Manganese(II) complexes of TzMorph2DO3A 
Two different manganese-containing complexes were isolated depending upon the 
solvent systems used for the crystallisation. 
Na2Mn2[Mn(II)2-(TzMorph2DO3A)2](TFA)2 - The slow evaporation of an aqueous 
solution of Mn(II)-TzMorph2DO3A leads to colourless plates with the structure reported 
in the figure 3.17. As shown the structure presents two manganese and one sodium atom 
in the asymmetric unit cell, bringing the metal : ligand ratio to 2 : 1, with the molecule 
crystallising in the triclinic space group P-1.
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Figure 3.17: Na2Mn2[Mn(II)2-(TzMorph2DO3A)2](TFA)2 complex structure
The structure displays six-coordinate manganese centres with a N3O3 donor set in a 
distorted trigonal prismatic molecular geometry (Figure 3.18), with one face occupied by 
three nitrogens of the macrocycle and the other face coordinated with three oxygens 
from the carboxylate arms. The unbound nitrogen is the one bearing the triazine moiety, 
again reflecting the influence of the triazine core on the donor properties of this ring 
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nitrogen. Considering the oxygen set, all the carboxylate arms are involved in the 
coordination contrary to that shown in the nickel or copper complexes where only two 
carboxylate arms were included in the coordination set, with the acid group opposite to 
the triazine moiety turned away from the metal centre. 
Figure 3.18: Na2Mn2[Mn(II)2-(TzMorph2DO3A)2](TFA)2 with triazine core omitted for clarity
The Mn – N and Mn – O bond lengths are 2.323(2), 2.349(2) and 2.296(2) Å and 
2.315(2), 2.138(19) and 2.207(19) Å respectively; all the distances fall in the range of 
previously reported Mn-O and Mn-N bonds in high-spin 6-coordinate species.[33] Contrary 
to other literature 7 or 8 coordinate structures this structure lacks weak coordination 
bonds that fall in the range of 2.77 - 2.91 Å.[34]
The carboxylate arms on the N7 and N9 are those coordinated to the Na atom 
through O3 and O7, and the metal centre is also a bridge between the second complex 
structure contained in the unit cell; the bond O35 - Na1 the sodium connects the two 
ligand molecules together. Finally the Na completes its coordination sphere with a 
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molecule of water and a trifluoroacetate anion; the trifluoroacetate is connected to the 
second manganese centre present in the structure as well, bridging the two metals.
The X-ray data also revealed a second manganese atom, completely free from the 
coordination of the macrocycle. It is possible to recognise a different geometry for this 
metallic centre, if the Mn coordinated to the macrocycle assumes a distorted trigonal 
prismatic geometry, for the second one is clearly a distorted octahedral geometry, with 
the equatorial axis formed by three molecules of water and the O8 provided by the 
trifluoroacetate anion. The axial bond distances are 2.248(2) and 2.218(2) Å and are 
occupied by a second trifluoroacetate molecule, not involved in any other bond and 
through the bond Mn2 - O35 with a carboxylate arm of the macrocycle.
The crystal lattice is supported by a network of hydrogen bonds, particularly between a 
water molecule coordinated to Mn2 (centred around O13), and O4 of a carboxylate group 
on the ligand. The proton involved in H-bonding was calculated to be 1.889 Å from O4, 
with this orientation allowing generation of a linear mono-dimensional layer (Figure 3.19). 
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Figure 3.19:  Na2Mn2[Mn(II)2-(TzMorph2DO3A)2](TFA)2 complex H-bond network (lateral and front view)
Mn5[Mn(II)4-(TzMorph2DO3A)4]Cl6 - The slow diffusion of acetone vapour into a 
concentrated aqueous solution of Mn(II)-TzMorph2DO3A gave long needles of a different 
manganese complex.
The crystals are tetragonal (Z = 2, two molecules for unit cell) in the space group I-4 with 
S4 symmetry. This compound has crystallised as cluster with a metal : ligand ratio of 9 : 
4 (Figure 3.20)
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Figure 3.20: Mn5[Mn(II)4-(TzMorph2DO3A)4]Cl6 complex structure (top) and asymmetric unit (bottom), 
chlorine atoms omitted for clarity
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The cluster has a Mn central atom in a slightly distorted octahedral geometry with the full 
coordination sphere occupied by water molecules. Contrary to complex with eight donors 
found in literature that present an octahedral geometry[34a] the asymmetric unit  shows 
how the metal linked to the ligand presents the same N3O3 set donor found in the first 
crystal structure, a distorted trigonal prismatic geometry, with one of the face occupied 
by the oxygens and the other by the nitrogens, with the nitrogen bearing the triazine 
complete free from coordination. 
 Also the lengths observed for the metal - nitrogen and metal - oxygen bonds are 
comparable to the ones found in the literature with compounds similar to the one 
synthesised,[33] with the distances Mn - N 2.397(5), 2.407(5) and 2.281(5) Å respectively 
and the bonds Mn - O 2.225(4), 2.233(4) and 2.143(4) Å.
 Finally there is another manganese atom acting as a bridge between two different 
ligand molecules. The metal presents a slightly distorted octahedral geometry, with one 
axial axis occupied by O6, the carboxylate arm borne on the N2, opposite to the triazine 
core and the O4 as equatorial axis, the carboxylate arm on the N3, next to the triazine 
moiety; finally the six coordination sphere is occupied by four molecules of water.
An interesting difference observed between the two crystallisation techniques is the 
difference in crystal polymorphs, which appears to be largely due to the H-bonding 
network. The slow evaporation method gave a largely supramolecular network which is 
absent in the crystal obtained via diffusion. In this case, the H-bond network is restricted 
to the central metal and the carboxylate arms of the ligand (Figure 3.21).
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Figure 3.21:  Na2Mn2[Mn(II)2-(TzMorph2DO3A)2](TFA)2 complex H-bond network presents the 
supramolecular network (top); Mn5[Mn(II)4-(TzMorph2DO3A)4]Cl6 complexes H-bond networks presents 
only an intramolecular network (bottom).
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3.5.1.4 - Vanadyl(IV) complex of TzMorph2DO3A 
H[V(IV)(=O)-TzMorph2DO3A] - Through the vapour diffusion of acetone into an aqueous 
solution of H[V(IV)(=O)-TzMorph2DO3A] it was possible to isolate light purple needle 
shaped crystals suitable for crystallographic studies. The analysis showed a monoclinic 
crystal system in the space group C2/c with three independent molecules in the 
asymmetric unit (Z = 3) and a total of twenty-four per unit cell.
Figure 3.22: H[V(IV)(=O)-TzMorph2DO3A] complex structure
As reported above the structure presents three independent molecules, all with a ratio 
metal : ligand equal to 1 : 1 (Figure 3.22).
The vanadium assumes a distorted octahedral geometry with a N3O3 donor set disposed 
in the facial fashion using all three cyclen donors but leaving the N-triazine moiety 
uncoordinated. The axial ligand site is occupied by the carbonyl bond (1.600(5) Å ) and 
the bond V - N18 (2.397(6) Å), nitrogen that bears a carboxylate arm not involved in the 
coordination sphere and is longer than those normally found in literature cyclen 
vanadyl(IV) complexes (average of 2.16 Å for the V - N bond).[35]
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This observation may be explained by the coordination of the equatorial set provided by 
the acid group that constrains the metal within the plane of the ring.
The equatorial set is composed of two of the two cyclen ring nitrogens, N16 and N17 and 
two oxygens, O14 and O13, from the carboxylate arms borne on these nitrogens. 
The octahedral geometry in this complex is strongly distorted, especially considering the 
bond angles of the compound (see table 2).
N17-V2-O13 77.09 O14-V2--N18 79.78 O13-V2-O16 99.42
N17-V2-N16 106.75 O13-V2-N18 90.74 O14-V2-O16 101.40
N16-V2-O14 81.38 N16-V2-N18 78.36 N16-V2-O16 91.70
O14-V2-O13 90.23 N17-V2-N18 78.36 N17-V2-O16 102.46
Table 2: H[V(IV)(=O)-TzMorph2DO3A] complex angles (°)
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3.5.2 - LANTHANIDE COMPLEXES OF TZMORPH2DO3A 
After the chemistry of d-block elements had been explored, attention was devoted to the 
lanthanide elements, it has been possible to synthesise lanthanum(III), europium(III), 
gadolinium(III), cerium(III), ytterbium(III) and lutetium(III) complexes.
3.5.2.1 - Europium(III) and Gadolinium(III) complexes of TzMorph2DO3A 
The europium(III) and gadolinium(III) complexes of TzMorph2DO3A are similar in 
chemistry, reactivity and structures and for these reasons they can be considered 
together. For both of the complexes suitable X-ray crystals have been obtained by slow 
evaporation of a mixture solution of water and methanol, collecting colourless plates for 
the Eu(III) and colourless blocks for the Gd in the triclinic system (Z = 1, one molecule 
for unit cell) and space group P-1, with a metal : ligand ratio of 1:1. Furthermore the 
structures are dimeric which is a common feature for lanthanide complexes and 
carboxylate bridged tetrameric structures of Tb(III) and Eu(III) have also been 
reported.[36] Thus these complexes contrast the predominately monomeric complexes 
formed by the d-block metal the d-block metals.[37] (Figure 3.23).
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Figure 3.23: {H4[Gd(III)2(TzMorph2DO3A)2]}4+ complex structure (top) and {H4[Eu(III)2(TzMorph2DO3A)2]}4+
complex structure(bottom) with counteranions omitted for clarity 
100 
Both of the complexes show a highly unusual coordination mode with all of the 
macrocyclic nitrogens donors uncoordinated. This is in strong contrast to the bonding 
mode displayed by the d-block complexes or in the literature for other Eu(III) and Gd(III) 
complexes in which the metal centre is universally bound by the macrocyclic N-donors.[38]
The metal cation is only coordinated by the carboxylate arms on the cyclen ring, with 
water molecules completing the 8 coordinate sphere. The carboxylate arm on the 
‘opposite’ cycle ring position to the to the triazine core is involved in a μ2
-
bridging mode 
between the two metals centres via a single carboxylate derived O-donor.
The europium(III) complex has a distorted square antiprismatic geometry, a very 
common geometry for carboxylate-substituted lanthanide complexes of cyclen, normally 
with the metal centre coordinated by the four nitrogens of the macrocycle ring and the 
three oxygens of the carboxylic acid.[39] The complex obtained, instead, displays a 
coordination sphere occupied by four water molecules, than the metal - nitrogen bonds, 
with three of them on a face of the square antiprism. The residual position is occupied 
by a metal - oxygen bond, namely the O6 borne on the N9 with a length of 2.374(3) Å. 
The other face instead is occupied by a water molecule and three oxygen atoms; the 
carboxylate arm on the N7 that has a bond distance equal to 2.367(3) Å, these distances 
are in the range that has been found in the literature about this kind of complexes.[36, 39-
40]
Finally the two residual sites in the coordination sphere are occupied by carboxylate arm 
on the N8, the one opposite to the triazine core bridging the two metal centres.
The O8-Eu1-O8 angle is 64.36(10)°, while Eu1-O8-Eu1 is 115.64(10)°; also the length 
of the bonds is symmetrical, with two opposite M-O bonds long 2.429(2) Å and the 
residual two 2.505(2) Å. It is eventually possible to calculate the distance between the 
two metal centres as 4.177(3) Å (Figure 3.24).
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Figure 3.24: the planar trapezoid in {H4[Eu(III)2(TzMorph2DO3A)2]}4+ complex
The gadolinium(III) is similar to the europium(III) complex with a distorted square 
antiprismatic geometry, and three water molecules occupying one of the face of the 
antiprism which is completed by the bond with the O12, oxygen on the N7 of the cyclen 
ring. The other face of the antiprism instead is taken by a residual molecule of water, the 
Gd1-O7 bond and the carboxylate pendants borne on the two N8 of the macrocycles. 
Analysing the length of these bonds, they result respectively 2.375(16) Å for Gd1-O7 and 
2.362(15) Å for Gd1-O12, in line with that has been found in the literature with an average 
of 2.35 Å for a Eu-DO3A based complex.[41]
As for the europium complex (Figure 3.24), the moiety formed by the two metal centres 
and the two O5, as bridges assumes a planar trapezoid conformation. Calculating bond 
distances and  angles result that the angle O5-Gd1-O5 is 64.33(6)°, while the angle formed 
by Gd1-O5-Gd1 equal to 115.67(6)°, considering the length of the bonds emerges that 
are longer than ones had been found in literature and perfectly symmetrical, resulting 
2.424(15) Å for the shortest and 2.500(15) Å for the longest side. Finally the distance 
between the gadolinium atoms has been calculated and found to be 4.169(15) Å, similar 
to that observed for the europium(III) complex. (Figure 3.25).
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Figure 3.25: the planar trapezoid in {H4[Gd(III)2(TzMorph2DO3A)2]}4+ complex 
3.5.2.2 - Lanthanum(III) complexes of TzMorph2DO3A 
For the La(III) complexes of TzMorph2DO3A it has been possible to grow two types of 
complexes as single crystals suitable for x-ray analysis. 
{Na2H4[La(III)2(TzMorph2DO3A)2]}2+ - Through the slow evaporation of aqueous solution 
of La(III)-TzMorph2DO3A have been obtained colourless plate crystals suitable for a X-
rays crystallography analysis.
The structure shows a metal : ligand ratio equal to 1 : 1, similar to the gadolinium or 
europium compound; in the crystalline system P21/n equivalent to the monoclinic crystal 
system has been found the presence of two molecule for every unit cell (Z = 2).
Like all the lanthanides analysed so far is possible to recognise some common  features; 
the macrocyclic nitrogens remain uncoordinated and the metal cations are bound by the 
oxygens on the carboxylate arms, with the O6 as bridge between the two lanthanum(III) 
centres (Figure 3.26).
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Figure 3.26: {Na2H4[La(III)2(TzMorph2DO3A)2]}2+ complex structure with counteranions omitted for clarity.
The lanthanum assumes a distorted tricapped trigonal prismatic geometry, that is 
common for lanthanide complexes,[42] with the coordination sphere completely occupied 
by the oxygens. Two spots are taken by the O6 provided by every ligand, as previously 
reported, the atom operates as bridge between the two metal centres forming a planar 
trapezoid conformation, with the La-O-La angle equal to 117.11(14)° and the O-La-O 
62.93(15)°, while the bond lengths La-O 2.589(4) Å and 2.565(4) Å respectively and the 
length La-La 4.397(2) Å, shorter than it has been found in literature[43] (Figure 3.27).
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Figure 3.27: the planar trapezoid of {Na2H4[La(III)2(TzMorph2DO3A)2]}2+ complex
One face of the distorted tricapped trigonal prism is then completed by one molecule of 
triflic acid, with the oxygen labelled O15 coordinating also a sodium atom; then a 
molecule of sodium hydroxide and the O8, an oxygen provided by one of the carboxylate 
arms of the macrocycle.
The second face of the prism is instead occupied by two molecules of water, the oxygen 
O4 of the carboxylate arm and the O6, provided by the carboxylate arm opposite to the 
triazine core and involved, as previously reported, in the coordination sphere capping 
the trigonal prism.
The bond lengths found are reported in the table 3 showing that on average the distances 
found are longer that the ones reported in the literature.[42-44]
Table 3: La-O bond distances (Å)
La1-O4 2.463(4) La1-O8 2.447(4) La1-O11 2.662(4)
La1-O6 2.566(4) La1-O9 2.509(4) La1-O14 2.705(4)
La1-O6i 2.589(4) La1-O10 2.507(4) La1-O15 2.617(4)
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The formation of the La(III) complex differed from other syntheses, where it was found 
that the pH necessary to precipitate the complex was reached by addition of Et3N. The 
resultant crude complex was recrystallised from methanol by slow evaporation of the 
solvent, to produce colourless hexagonal prism crystals suitable for X-rays analysis. 
The unit cell presents six molecule for unit (Z = 6) in a 1 : 1 ratio between the metal and 
the ligand and disposed in the R-3c:H crystal system. 
Some features show how the complex is completely different to the lanthanide 
compounds presented so far (Figure 3.28).
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Figure 3.28: {NaH6[La(III)6(TzMorph2DO3A)6]}7+ complex structure (top) and asymmetric unit (bottom), 
counteranions omitted for clarity
The complex is not obviously a dimer and there is no characteristic planar trapezoid 
orientation of the oxygens donors and the metal centres. An interesting characteristic is 
that the metal is bound within the ligand cavity, with all the 4 ring nitrogen and 3 
carboxylate donors coordinating the La(III) centre. Most interestingly the structure 
reveals the loss of the triazine core. We interpret this observation as the strongly Lewis 
acidic La(III) cation renders the triazine core even more electron deficient and 
susceptible to nucleophilic attack by water or hydroxide (the complex was prepared at 
elevated pH values) at the ipso-carbon position. This is not observed in the above Ln(III) 
complexes since the N-triazine donor is not bound to the metal centre.  
 The metal centre has a coordination number of ten in a distorted bicapped square 
antiprismatic geometry. The capping bonds are formed by the lanthanum and the N2, a 
nitrogen of the cyclen ring, and O1, a carboxylate arm that is used as bridge between 
two metal centres, measuring 2.917(5) Å and 2.749(4) Å respectively, these result much 
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longer than the common capping bond found in literature with an average length of 2.56 
Å.[42] One face of the square antiprism is occupied by N5, the nitrogen that had borne the 
triazine core, O6 and O2, borne on the macrocycle and O7 supplied by sodium 
hydroxyde found in the centre of the compound and coordinated to all six lanthanides.
Finally the other antiprism face is occupied by the remaining nitrogen donors of cyclen 
ring, O4 from the last carboxylate arm left and O3 provided by a different carboxylate 
arm of a ligand molecule.
It is possible to see that the change in geometry leaves the metal-oxygen bond distances 
in the same range of measurements (2.47 - 2.55 Å) compared to the above structures. 
Contrary to what has been found in the literature, the range of metal - nitrogen bond 
lengths are longer in for this material; 2.80 - 2.91 Å for the nitrogens bearing a 
carboxylate arm. It is also interesting to note that the length between the metal and the 
nitrogen that was bearing the triazine core is shorter, M - N5 is 2.707(6) Å, than the 
common distance found in the literature,[42, 44b] but also the release of the triazine 
changed the length of the bond completely, indeed for all the compounds until now 
discussed the M - Ntriazine bond was the longest one of the M - Nmacrocycle bonds. This is 
due to the electron withdrawing effect of the triazine core. With the release of this moiety 
of the molecule it is possible to measure a stronger binding effect that results in a shorter 
bond length.
It has been proved that changing the pH of the solution adding an excess of base 
like Et3N has the effect to modify the coordination geometry of the compound and to 
release the triazine core as leaving group, in particular this feature could be used in future 
to develop new compound investigating the role of the pH in the release of the triazine 
core or using different leaving groups to understand their behaviour at assorted pH.
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3.5.2.3 - Lutetium(III) complex of TzMorph2DO3A 
Crystals suitable for a solid state analysis have been grown by slow evaporation of a 
concentrate aqueous solution of Lu(III)-TzMorph2DO3A.
The data show that the lutetium compound forms a 1 : 1 metal : ligand ratio, with the 
molecule crystallising in the triclinic space group P-1 and with two independent molecule 
(Z = 2) in the unit cell (Figure 3.29).
Figure 3.29: H2[Lu(III)-TzMorph2DO3A]Cl2 complex structure.
The Lu(III) presents a distorted square antiprismatic geometry, and like several of the  
complexesdescribed above the macrocyclic nitrogens are uncoordinated. This is 
different also considering the kind of bonds found in the literature about lutetium(III) 
complexes, with the metal centre always being coordinated through the macrocyclic N-
donors.[45] A peculiar characteristic of this compound is that, even if it is a M(III), the 
coordination is provided only by two carboxylate arms on the cyclen ring, 2.311(4) and 
2.312(4) Å respectively, and with a comparable Lu-O length found in the literature (2.2-
2.3 Å).[45a, b] The eight donor coordination sphere is occupied by the two oxygens 
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provided by the acid groups and completed by six molecules of water arranged in a 
distorted square antiprismatic geometry. One face is occupied by four oxygens: O9, O10, 
O12 and O14 all from molecules of water; the second face instead is occupied by two 
oxygens provided by molecules of water (O11 and O13) and two provided by the 
carboxylate arms, O6 and O8. Finally an interesting characteristic of this compound is is 
the the charge on complex. Since the the Lu(III) is coordinated only by two carboxylate 
groups this leaves a positive charge to balance. Furthermore the structure presents two 
amine groups of macrocycle protonated, N7 and N9 (the hydrogens in the figure 3.28
have been removed for clarity), bringing the total positive charge to be balanced to +3. 
Considering the secondary coordination sphere in the structure there are one fully 
occupied Cl- and two 50% occupied Cl- able to provide a -2 negative charges. The final 
positive charge is balanced by the free carboxylate arm that is deprotonated, but not 
involved in the first coordination sphere of the compound, leaving the complex neutral. 
This behaviour is unique amonst the complexes in this study.
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3.5.3 - LIGAND AND COMPLEXES DIPYRIDAMOLE MIMIC SYNTHESIS
After exploring the chemistry of M-TzMorph2DO3A a mimic ligand of dipyridamole has 
been synthesised. Adopting the same conditions used to develop the symmetrical di-
morpholine triazine core it has been possible to synthesise an asymmetrical triazine core, 
employing piperidine and diethanolamine as nucleophilic substituents. The final steps 
were the addition of the cyclen core and then the release of the protection group by the 
addition of TFA. The synthetic path is reported below in figure 3.29, instead all the details 
about the conditions used and the full characterisation of the ligand are described in the 
experimental section.
Figure 3.30: synthesis of TzPipDEA-DO3A ligand 
To synthesise the complexes TzPipDEA-DO3A (0.16mmol) was dissolved in ca. 3mL 
of water and the pH of the solution corrected to reach pH 7, adding a solution of 1M 
NaOH. The metal salt, typically as a chloride, triflate or nitrate, was dissolved in ca. 
2mL of water and added to the ligand solution. The solution was heated at 40-50°C for 
five minutes and then cooled to room temperature. The mixture was purified by flash 
chromatography on a short column, to afford a clear solution, then the compounds 
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have been characterised by mass spectroscopy and all the results are reported in the 
experimental section (Figure 3.31). 
Figure 3.31: method synthesis of TzPipDEA-DO3A complexes
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3.6 - CONCLUSION
In this chapter has been described the formation of twelve novel complexes using the 
metals Cu(II), Mn(II), Ni(II), La(III), Y(III), Eu(III), Gd(III), VO(II), Co(II), Ce(III), Yb(III) and 
Lu(III) with the ligand TzMorph2DO3A. Furthermore it has been investigated by 
spectroscopy, using the Job's method, the empirical formula of the ligand, resulting with 
the presence of three molecules of TFA. Always through a UV spectroscopy studiey has 
been investigated the structure of three complexes (Cu(II), Co(II) and Ni(II)) in solution. 
Analysing the data and comparing with the literature results that the copper compound 
presents a trigonal bipyramid structure, suggesting that the metal centre is coordinate by 
a N3O2 system.  
 The nickel complex instead, shows as an evident distorted six coordinate species, 
with a N3O3 donor system, it is not impossible to exclude that the species could exist in 
equilibrium or mixture with a square planar N2O2 donor system, due to the presence of 
a band at 540 nm. Finally the Co(II) complex has been hypothesised that presents an 
octahedral geometry system in solution based on N3O3 donors. 
Single crystal X-ray diffraction data was collected successfully for several metals. The 
data can be analysed dividing the metals in similar group.  
 The d-block metals Ni(II), Cu(II), Mn(II) and V(IV) in solid state present some 
communal characteristic, the metal is inside the macrocycle, coordinated by the nitrogen 
of the cyclen ring and by the carboxylate gropus as pendant donors. Furthermore all the 
metals present a longer M-Ntriazine bond (or even not coordinated), this is due to the 
triazine core of the compound, being the moiety very electron deficient this affect the 
donor capacity of the amine, resulting in a weaker M-N bond. 
 The lanthanide complexes (Eu(III), Gd(III) and La(III)) instead present a dimeric 
structure, forming a perfect planar trapezoid between the metal centres, moreover the 
metal is outside the macrocycle, not coordinated at all by the nitrogens, feature 
absolutely inusual and not found in literature. The only two exceptions to these general 
characteristic are the Lu(III) complex, that does not present the dimeric structrure and it 
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is coordinated by only two carboxylate arms, and the La(III) complex obtained 
synthesising the complex at basic pH. In this last structure the lanthanide is found inside 
the cage coordinated by the cyclen ring too, but more important the structure does not 
show the presence of the triazine core anymore; working at pH around 11 indeed could 
be the cause to make the triazine core acting like leaving group. 
Finally a new dipyridamole mimic ligand has been synthesised and fully characterised 
(TzPipDEA-DO3A), moreover seven novel complexes has been obtainted using the 
metal Cu(II), Mn(II), Ca(II), La(III), Y(III), Eu(III), Gd(III) and VO(II) and characterised by 
MS. Further studies could be conducted on this versitile new ligand to understand the 
coordination chemistry of these novel complexes and to deveop their radiochemistry.
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CHAPTER 4 
BENZOTHIAZOLE LIGAND SYSTEM 
119 
4.1 - BENZOTHIAZOLE CORE INTRODUCTION
 Alzheimer's disease (AD) is the most common form of dementia in elderly people. 
It is a neurodegenerative disease associated with chronic dementia, memory loss and 
cognitive impairment, ultimately causing death as the brain effectively shuts down. At 
present, according to the World Health Organisation (WHO), worldwide 47.5 million 
people have dementia, with every year 7.7 million new cases projecting the total number 
of people with dementia to 75.6 million in 2030 and 135.5 million by 2050.
Currently there is no treatment available to cure dementia or to alter its progressive 
course and also there are no imaging techniques for a definitive diagnosis of Alzheimer's 
disease. In order to obtain a diagnosis, a system is used whereby the patient is assessed 
by cognitive tests[1] like Mini-mental state examination[2] evaluating the cognitive 
functions. Although different laboratory tests are used for a probable AD diagnosis, at 
this moment a definitive diagnosis can be obtained only post mortem. 
Thus the development of an imaging agent is essential to get early and more accurate 
diagnosis in the first stages of the disease.
 The cause for most Alzheimer's cases is still unknown but some hypothesis have 
been proposed to understand the onset of progressive cognitive decline that 
characterises the disease. One of the most accepted hypothesis is based on deposition 
of senile plaques, composed of β-amyloid (Aβ) plaques and neurofibrillary tangles 
composed of hyperphosphorylated tau proteins, found in high concentration in brain 
tissue affected by the disease making them neuropathological markers for AD.[3] 
 At the base of the amyloid hypothesis there is the imbalance between the beta-
peptide (Aβ) production and Aβ clearance; the Aβ amyloid is formed by the amyloid 
precursor protein (APP) where Aβ are a normal product of APP metabolism by the 
enzymes: the β-secretase and γ-secretase (Figure 4.1).
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Figure 4.1: The APP membrane is shown in light orange and the peptide, embedded into the membrane, 
in green. The enzymes cleave Aβ at the two red points indicated (the length shown is not 
representative of the actual length) (Thomas, Cardiff University, 2013)
Mutations in the APP gene could cause the Aβ deposition, the mutations promote the 
cleavage of slightly longer Aβ (Aβ1-42 as opposed to Aβ1-40) that are insoluble and, hence, 
accumulate together, along with Aβ1-40, to form toxic oligomers.[4] While soluble forms of 
Aβ have been shown to cause synaptic damage[5], the insoluble plaques are thought to 
be the initiator of AD but not directly cause the physical outcomes of the disease. It is 
thought that the insoluble Aβ oligomers initiate the hyperphosphorylation of the 
microtubule stabilising protein tau.[6] Once hyper-phosphorylated, the tau protein can no 
longer bind to microtubules (Figure 4.2) and so aggregate together forming neurofibrillary 
tangles. This leaves the microtubule to disintegrate and leads to apoptosis of neurons.[7] 
Figure 4.2: Tau protein (blue) shown binding to a microtubule (pink) before being phosphorylated and 
disassociating after being hyper-phosphorylated[6] 
β-secretase
γ-secretase
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Hence, the development of an imaging agent that could highlight the presence of Aβ in 
vivo rather than via autopsy could give a better understanding of the onset of the disease 
and improve the possibility for prevention or treatment. Although the structure of Aβ 
plaques has been difficult to obtain, it is thought that they have a cross-β sheet structure, 
where the β sheets run in a direction parallel to the fibril axis but the strands run 
perpendicular to the axis[8] (Figure 4.3). This conformation leaves two different sides of 
the protein with different features, hydrophobic sections in between the sheets and 
hydrophilic sections around the sheets.
Figure 4.3: Aβ structure[8] 
Complexes based on 2-arylbenzothiazole, or similar derivatives, have become of great 
interest due to their many uses[9]. Benzothiazole derivatives have found applications as 
anticancer,[10] anti-inflammatory,[11] anti-tuberculosis[12] and anti-microbial agents,[13] and 
of relevance to this work as Aβ plaque imaging agents.
Currently the only imaging agent approved by the FDA is florobetapir-18F,[14] while 
compounds based on the benzothiazole core like thioflavin T (ThT) or Pittsburgh 
compound B (PiB) are in trial phases (Figure 4.4).
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Figure 4.4: (a) florobetapir-18F, (b) ThT, (c) PiB
Thioflavin T is a well-known structure based on 2-arylbenzothiazole used to stain 
amyloids such as Aβ, but unfortunately ThT is not specific for amyloids of Aβ as it reacts 
with many types of amyloid fibrils.[15] A study led by LeVine in 1993 showed the 
interaction between the amyloid plaques and the ThT can be followed by luminescence, 
the molecule binding to synthesised aggregated Aβ(1-28) and Aβ(1-40) shows a new 
excitation (absorption) wavelength at 450nm, while the emission wavelength was red-
shifted from 445nm to 482nm[16] (Figure 4.5).
Figure 4.5: ThT absorption spectra (left) and emission spectra (right), in absence of Aβ plaques, 
with Aβ(1-28) and Aβ(1-40)[16]
The fluorescent changes in the emission spectrum, in fact, occur only when the molecule 
binds aggregate oligomers of Aβ and not monomeric or dimeric species. This feature 
makes this compound highly suitable to image in vitro the harmful oligomeric plaques. 
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Unfortunately the study does not provide any explanation about how the molecules are 
bound to the β-sheets. 
 Krebs et al[17] investigated the conformation assumed by the ThT as dye when 
bound to the plaques by confocal microscopy and polarised light. It has been observed 
that when exciting the dye with polarised light the fluorescence from the molecule formed 
a consistent pattern rather than an uniform disc. As polarised light was used, this pattern 
can only occur if the ThT molecules are bound to the amyloid fibrils in a regular, aligned 
way. Therefore, through knowing which way the amyloid fibrils lay and when the ThT 
molecules become excited by the polarised light, the study revealed that Thoflavin T 
must bind perpendicularly to the amyloid fibrils but in the direction of the fibril axis in 
channels in the β-sheets (Figure 4.6).
Figure 4.6: β structure of amyloid fibrils (a).“Channel” model of ThT binding to fibril-like β-sheets (b)[18]
In agreement with this there are the studies led by Biancalana,[18] and Wolfe[19] who 
showed that the ThT behaves like a "molecular rotor". Their analysis demonstrated 
variation in the photophysical properties during the rotation of the benzothiazole moiety. 
In fact, in solution the low-energy barrier allows the benzothiazole and benzylamine rings 
to rotate freely about their carbon-carbon bond and it was believed that the increase in 
ThT fluorescence results from the selective immobilisation of a subset of Thioflavin 
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conformers. The results showed how the rotation quenched excited states, causing low 
fluorescence emission for free ThT.
Opposite to that, the immobilisation of the molecule preserved the excited state, resulting 
in a high quantum yield of fluorescence. In this way, in conclusion, the Aβ fibrils are likely 
to provide a binding site that can lock the ThT molecule, increasing the fluorescence 
emission of the compound.
Since Thioflavin T has revealed itself as such a good imaging agent for Aβ plaques 
in vitro, different attempts to produce a similar structure that could be used for in vivo
imaging has been undertaken.[20] Different studies led to the conclusion that removing 
the charge from the 2-arylbenzothiazole derivatives increases the lipophilicity of the 
compounds, allowing an easier crossing of the blood-brain barrier (BBB) and also 
showing much higher affinity for Aβ (1-40) fibrils.[20c] Moreover it has been noticed that 
the removal of the methyl group on the heterocyclic nitrogen of ThT can improve binding 
affinity to β amyloid plaques as well.[20b] Finally these studies showed how also the 
presence of only one methyl group on the amine nitrogen in the 4'-position increased the 
affinity but for unknown reasons. This is an important feature for the synthesis of new 
derivatives, leaving the amine group free for possible further functionalisation.
 For examples of this important characteristic show how, through the use of a linker, 
it could be possible to bind a macrocycle or a ligand moiety to coordinate an appropriate 
metal for imaging or with theranostic application.
 Recent examples include the synthesis and the develop of MRI agents, bringing a 
TACN or the DO3A ring as chelator (Figure 4.7) for a gadolinium metal centre and using 
the chloroacetyl chloride as linker between the coordination site and the benzothiazole 
moiety.[21]
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Figure 4.7: examples of DO3A (left)[21d] and TACN ligand (right)[21a] with a benzothiazole moiety 
126 
4.2 - SYNTHESIS OF BENZOTHIAZOLE LIGANDS
The synthesis of a benzothiazole can follow many different paths, one of the most 
common approaches is the direct synthesis of a 2-arylbenzothiazole via palladium 
catalysed C-C bond formation between a benzothiazole and an appropriately substituted 
aryl.[22]
Another common method is through the condensation of 2-aminothiophenol with 
different functionalities on an aryl group using polyphosphoric acid as solvent to promote 
the condensation.[23]
 The mechanism of the condensation follow the nucleophilic attack of the amine on 
the carbonyl to form a Schiff base with elimination of a molecule of water, then the ring 
closure follows the nucleophilic attack of the sulfur on the double bond formed and finally 
the oxidation of the secondary amine to a tertiary (Figure 4.8).[24]
This method has been chosen for the synthesis of the precursor derivatives. Heating in 
polyphosphoric acid as solvent or in ethanol, and neutralisation with a solution of 10% 
Na2CO3 gives the desired compound.[20a, 25]
Figure 4.8: condensation mechanism of 2-aminothiophenol with carbonyl derivates
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As described above, with the example of chloroacetyl chloride, a linker is necessary 
between the two moieties of the compound. Several attempts have been made to 
prepare new ligands. The experimental section includes the attempted failed syntheses 
of new intermediates. These include the ring opening of succinic or diglycolic 
anhydrides[26] or the use of Traut's reagent with deferoxamine.[27]
 Successful attempts to generate a linker species from reaction of an excess of 
epichlorohydrin with 4-(benzo[d]thiazol-2-yl)-N-methylaniline. Dissolving the two 
compounds in ethanol under nitrogen, and refluxing them for three days, then the solvent 
and the excess of epichlorohydrin have been removed in vacuo. The residue was 
recrystallised in Et2O and the solid filtered off before to be purified by chromatography 
column (Figure 4.9). 
Figure 4.9: first step of the precursor synthesis
The second step has been the closure of the epoxide ring, stirring the chlorohydrin 
precursor with a base, under nitrogen in methanol at room temperature, followed by an 
aqueous work-up to afford the product. (Figure 4.10).
Figure 4.10: second and final step of the precursor synthesis
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Using this route a versatile novel precursor (Bz-epox), has been synthesised and fully 
characterised. Reacting the epoxide function via nucleophilic substitution makes it 
available to a wide range of new possible chelating agents. This is discussed in the 
following section.
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4.3 SYNTHESIS OF COMPLEXES
4.3.1 - DO3A based complexes
As discussed in the previous chapter, DO3A is an azamacrocycle suitable to coordinate 
a diverse range metals for imaging purposes.[28] Thus DO3A and Bz-epox were 
combined in ethanol and Et3N and the solution heated at 50-60° for 24 hours. The second 
step of the synthesis was the removal of the carboxylate tBu protecting groups via 
treatment with adding trifluoroacetic acid to yield a green oil. Complexes were prepared 
by the reaction of an aqueous methanol solution of ligand with an aqueous solution of 
the appropriate metal salt at pH 7 and 50°C. The mixture was purified by flash 
chromatography on a short column, to afford a clear solution (Figure 4.11).
Figure 4.11: synthesis of M-DO3A-Bz-epox complexes, all the characterisation data are reported in the 
experimental section
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4.3.2 - DFO based complexes
The approach to synthesise the complexes containg DFO was different from that used 
for the previous compounds. Initially DFO is protected by complexation to a metal centre. 
Followed by the addition of the Bz-epox to the mixture (Figure 4.12).
Figure 4.12: synthesis of DFO-Bz-epox complexes
4.3.3 - Cyclen based complex
Cyclen has proved to be an excellent chelator for cold copper,[29] even if the stability of 
the compound in vivo is lower. The study by Jones-Wilson et al showed that complexes 
of cyclen, including cyclam, DO2A, DOTA and TETA form highly stable complexes with 
Cu(II). Surprisingly, the potential neutral DO2A complex was the least stable of those 
species (Log Kf (CuII) = 18.9). This study also showed that the systems examinated were 
bioavailable, but that neutral and cationics show higher organ absorption.[30]
 Working at different pH, it could be possible to deprotonate the hydroxy group 
presents on the compound, giving a total charge of +1, changing the coordination 
chemistry of the complex, filling the coordination sphere of the copper,[29, 31] and making 
the compound more likely to cross the blood-brain barrier. 
Thus the azamacrocycle was dissolved in acetonitrile and Bz-epox was added to the 
solution. The mixture was left under stirring for three days, then the solid filtered off and 
the solvent removed in vacuo, later the residue was dissolved in MeOH; a solution of 
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CuSO4*5H2O was dissolved in MeOH and added to the ligand. The solution was heated 
to 50°C for five minutes, changing colour in a dark blue solution. The solution was cooled 
to room temperature and filtered off on a small chromatography column (Figure 4.13).
Figure 4.13: synthesis of cyclen-Bz-epox complex
132 
4.4 - FLUORESCENCE MEASUREMENTS
The benzothiazole ligands and complexes showed an interesting activity as 
luminescence probes that has led to their investigation in more detail. All the ligands and 
complexes synthesised and described in the previous paragraph have been measured 
by Dr. Simon Pope's research group (Cardiff University), unfortunately due to the 
different solubility of the compounds it was not possible to use the same solvent system, 
thus the results will be discussed dividing the compounds into discreet groups.
Initially for all the compounds 10-5 M solutions (except for the ligand DO3A-Bz-epox that 
was 10-6 M) were used for measuring the UV spectra and then the same solution used 
for the luminescence spectra at room temperature and the results obtained in terms of 
λabs, λem and Ʈ are reported in the underlying table.
Compound λabs (nm)d λem (nm) Ʈ (ns) e
Bza
353.5 (22000), 313.5 (16800), 229.5 
(51000)
410 1.54
Bz-epoxa
353 (40800), 302 (17600), 229 
(113900)
407 1.53
DO3A-Bz-epoxc 368 (1287000) 434 1.83
Cu-DO3A-Bz-epoxc 364.5 (5200) 432 1.83
Eu-DO3A-Bz-epoxc 364 (8300) 433 1.82
Tb-DO3A-Bz-epoxc 364.5 (5000) 431 1.74
VO-DO3A-Bz-epoxc 364.5 (6300) 433 1.82
Ga-DFO-Bz-epoxb 358 (27900), 225.5 (53800) 427 1.85
Eu-DFO-Bz-epoxb 358 (22900), 319 (16300), 228 (40500) 428 1.81
Cu-cyclen-Bz-epoxc 361 (2300) 431 1.82
a DCM; b 1:1 EtOH:H2O; c 1:1 H2O:DMSO; d λex lowest energy from corresponding UV;    e 
λex = 372 nm
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Analysing the data (Figure 4.14 and 4.15) is possible to see from the spectra that there 
are no peaks characteristic of lanthanide emission, under the conditions used to excite 
the compounds.
Figure 4.14: emission spectra of DO3A-Bz-epox and related complexes
Figure 4.15: emission spectra of DFO-Bz-epox complexes 
Thus, it is obvious that the spectrum of all these species are essentially identical, being 
dominated by ligand centred emission. It is also possible to conclude that there is no 
significant energy transfer to the metal centres. 
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One of the possible cause why there is not energy transfer could the distance between 
the antenna and the lanthanide metal centre. According to Förster's theory of resonance 
energy transfer (FRET), the distance between the donor species (the organic fluorophore 
as antenna) and the acceptor (the metal centre) is in the range of 8-10 Ᾰ.[32] The complex 
of Tb(III) and Eu(III) DO3A-Bz-epox show a distance of 8.65 Ᾰ. The lack of electronic 
communication between the fluorophore and the metal suggest that the distance (8.65 
Ᾰ in this case) is too great for any significant energy transfer and/or the relative 
orientation of the fluorophore and the metal is unsuitable for energy transfer. 
More likely the absence of the lanthanide peaks could be the consequence of a poor 
overlap of the energies states between the metal centre and the excited states of the 
ligand. Unfortunately studies about the energy states has not been done as part of this 
work; possible future studies will be useful to explain and understand the energy levels 
of the compounds and if the absence of an efficient overlap of the electronic states is 
the main reason of the lack of the energy transfer to the lanthanide centres. 
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4.5 - CONCLUSION
This chapter has described the synthesis of several benzothiazioles (and their 
precursors), and the formation and characterisation of three new kind of ligands based 
on an appropriate benzothiazole moiety (Bz-epox). These benzathiazole derivatives 
have been further coupled to several coordinating molecules to obtain a new versatile 
group of ligand, able to bind several different metals. 
 These ligands have been used to form a number of species; DO3A-Bz-epox
complexes have been formed containing Cu(II), Tb(III), Eu(III) and VO(II), while DFO-
Bz-epox has been reacted with Eu(III) and Ga(III) to form novel complexes. Furthermore,
cyclen-Bz-epox was used to successfully form a novel Cu(II) complex. All complexes 
were synthesised using a 1:1 metal:ligand ratio and characterised by EMI-MS to confirm 
binding of the metal in solution. 
Finally a spectroscopic study of the ligands and the complexes has been described. The 
data shows that under excitation, there are no peaks characteristic of lanthanide 
emission, leaving the luminescence properties dominated by ligand centred emission 
and suggesting that there is not significant energy transfer to the metal centres.  
 The reasons behind this result have been discussed. It has been hypothesised that 
the reasons for this observed lack of energy transfer is due to the orientation of the 
fluorophore and the metal, and that the distance between the antenna and the lanthanide 
metal centre (8.65 Å for the complexes) is too great for any significant energy transfer. 
Alternatively, it may be that poor overlap of excited energy levels between the metal 
centre and the ligand prevents fluorescence. Future studies could examine this in more 
detail to determine the main reason for the observed lack of energy transfer to the 
lanthanide centres. 
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CHAPTER 5 
48VANADIUM PET DATA
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5.1 - 48VANADIUM PET DATA
The interest in new accessible radioisotopes for PET has lead the research to be more 
focused on metals in the recent years. 48V, with its 16 days of half-life value would be 
generally useful for process with slow pharmacokinetics. 
 As introduced in the Chapter 1 the metal radioisotopes present some advantages 
compared to the organic molecules. As example it is possible to make a comparison 
between the most used isotopes 18F and 48V, the metal used to test the ligand Bz-epox-
DO3A for PET studies. 
Both of the isotopes decay mainly emitting β+, but more interesting with similar energy, 
633 keV for the 18F and 694 keV for the metal. Considering these levels of energy the 
positrons do not travel far before to be annihilated by electrons (the mean free path); 
allowing a better localization of the targeting compound. 
The main advantage of radiometals, is the longer half life, if the 18F has a half life of 110 
mins, while 48V is 16 days; pragmatically this feature allows scans over an imaging 
timescale that is impossible for main group radiotracers. 
 Finally, we should note that, 48V is not a pure β+ emitter, but it is also an γ-emitter. 
These high energy γ-emissions at 944, 983 and 1312 keV are easily filtered in PET 
detection. These are the electrons downscattered by in the environment, to lower 
energies, interfering with the photons that can be visualised by the detector.[1] 
All the features have lead to use the 48V as possible radiotracer for PET studies and the 
develop of new or modified ligands capable to coordinate the metal. The compound V-
Bz-epox-DO3A, reported in the Chapter 3, has showed suitable features to be 
considered suitable for further studies in vivo. 
5.1.1 - Production and purification of 48V 
The 48V has been produced and purified by Dr Stephen Paisey at PETIC (Cardiff 
University), adapting the procedure developed by Mainardi's group.[2] Production used a 
cyclotron with a target process of 48Ti(p, n) 48V. The purification was achieved by 
141 
digestion of target (H2SO4 - HF) and then an alkaline aqueous work-up and purification 
on a resin column. The supernatant has been corrected to pH 3-4 by addition of diluted 
HCl and the solution was passed through a resin column. The 48V is retained in the 
column as cationic species and then eluted with a solution of 20% ammonia; the solution 
was neutralised with diluted HCl and once dry dissolved in the desired media. 
5.1.2 - Radiolabelling and results 
The studies with 48V have been carried at PETIC (Cardiff University) by Dr. Stephen 
Paisey, with mice provided by Professor Paul Morgan and Dr. Timothy Hughes's 
research group, Cardiff University. 48V was supplied by PETIC as an oxalate solution 
(0.01 M) in aqueous solution at pH 7. At this stage the exact speciation of this complex 
is unknown. 
The 48V was supplied with an activity of 1 MBq, while the radiolabeling efficiency 
was determined through the use of paper ITLC strips; initially we used the method 
adopted for "cold" metal complex preparation in the Chapter 4, using a silica TLC eluent 
of 1:1 H2O : MeCN. Under these conditions V-Bz-epox-DO3A showed on a silica TLC a 
value of Rf = 0.7. 
In a different way the "hot" complex did not show the same behaviour at these conditions, 
remaining on the baseline; thus the choice has been moved to utilise as eluent the 
standard method applied for the 89Zr.[3] 
As reference compound, we employed neutralised 48V in 0.1mM oxalic acid with 50mM 
DTPA as eluent. For V-Bz-epox-DO3A to a solution in water of the ligand has been 
added free 48V oxalate and the pH of the solution corrected to 7 by addition of 0.1M 
NaOH.Radio-TLC was run with 50mM DTPA as eluent system, showing that the 
coordinated compound remains on the baseline. The two overlaid radio-TLCs traces are 
shown in figure 5.1. 
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Figure 5.1: overlaid radio-TLCs of coordinated compound (red) and 48V oxalate (green)
This effective complexation obtained has led to further studies and allowed a study in 
vivo PET-CT on a murine (mouse) model of Alzheimer's disease. Figure 5.2 illustrates 
the PET-CT scan obtained 43 hours after injection. 
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Figure 5.2: In vivo PET-CT images of 3TG C6 con +/+ Alzheimer's’ disease mice 43 hours after injection.
LHS = 48V complex uptake in liver and spleen,  
RHS = 48V oxalate uptake in liver spleen lungs and bone/joints
The maximum intensity projection (MIP, top left image) shows the distribution of the two 
compounds in the mices. The left mice has been exposed to the new synthesised "hot" 
complex and it is possible to see how the 48V has been detected only in liver and spleen, 
not surprising, considering that are organs normally involved in the excretion of 
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molecules from the body. This suggests the compound unfortunately is not able to cross 
the blood-brain barrier (BBB), indeed there is not sign of any uptake of activity in the 
brain where the β-amyloid plaques are located. 
The animals on the right of the image were injected with the free 48V oxalate 
solution, and from the data apparent that there is an accumulation of radiation in liver, 
spleen, lungs and bone/joints. Again this implies that free 48V beyond to be found in the 
organs designed to the excretion of molecules is not uptake clearly in the brain, being 
not able to cross the BBB, but instead can be accumulated in other region and/or organs 
of the body. 
This results shows how, even if the new compound is not able to cross the BBB, 
that the complex has good stability in vivo and the animals injected with the 48V-Bz-epox-
DO3A does not show any presence of hot metal in another area or organs except liver 
and spleen, similar to the "free" 48V. 
This study may be regarded as a toxicology experiment in which the subject tolerated 
both the "free" 48V oxalate and the 48V-Bz-epox-DO3A complex used. Work in the group 
continues to develop more effective elucidator for this exacting new tracer. 
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5.2 - CONCLUSION
This chapter has described the production and purification of the 48V isotope that has 
been used as radiometal with the ligand Bz-epox-DO3A. It has been shown that 
successful complexation of 48Vn by the ligand generated 48V-Bz-epox-DO3A; the 
radiometal with an activity of 1 MBq, and binding efficiency tested using paper ITLC strips 
using the standard method applied to 89Zr shown previously. This showed that the ligand 
fully complexed the radiometal. 
 Finally the 48V-Bz-epox-DO3A has been tested in vivo on a murine (mouse) model 
of Alzheimer's disease. Combined PET/CT imaging indicates that the complexed 
radiometal is not able to cross the blood-brain barrier, but shows a good stability in vivo, 
with accumulation of the radiotracer only in the liver and spleen and overall with good 
tolerance of the test subject to both the "free" 48V oxalate and the 48V-Bz-epox-DO3A
complex. 
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